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Abstract
We consider the analysis of data from the MRC Multicentre Trial for Early
Epilepsy and Single Seizures (MESS), which was undertaken to assess the dif-
ferences between two policies: immediate, or deferred treatment for patients
in early epilepsy. In studies of recurrent events, like epileptic seizures, there is
typically lots of information about individuals' seizure patterns over a period
of time, which is often not fully utilised in analysis. We develop methodology
that allows pre-randomisation seizure counts and post-randomisation times to
rst seizure, and from rst to second seizure, to be jointly modelled, assuming
that these outcomes are predicted by (unobserved) seizure rates.
The joint model was found to be superior to standard survival methods. The
model had more power to detect statistically signicant covariate eects not
found by standard survival analysis, however, interesting characteristics within
the data, not present in the model were also highlighted. The simple joint
model was extended to acknowledge these characteristics.
The results suggested that the identically distributed assumption for the sur-
vival times may not be accurate. Instead we adjusted the model to allow for
changes in seizure rate both at randomisation and following a seizure post-
randomisation.
There is evidence to suggest that there may be a substantial subset of the
MESS sample containing individuals who we would not expect to experience
seizures post-randomisation. If survival data has a proportion that are im-
mune to the event of interest, a model that ignores this may give misleading
results. We considered a cure rate model that allows the separation of in-
dividuals who will never experience seizure recurrence and those who are at
risk of future seizures. We can then formulate probabilistic models for the
`at risk' individuals. These modications to the simple joint model have been
considered both in isolation and together in a full model.
xiii
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Chapter 1
Introduction
This thesis builds a number of models that can be used in the analysis of data
that arrive in the form of event counts and survival times. This work is moti-
vated by individual patient data from a randomised controlled trial that was
undertaken to address the question of whether immediate or deferred treat-
ment should be favoured for patients that are in the early stages of epilepsy.
A baseline seizure count is recorded for each individual, with the associated
number of days over which the seizures were observed and the seizure types ex-
perienced. We consider post randomisation times to rst and second seizure.
Time to rst seizure is an internationally agreed outcome in epilepsy trials
(ILAE Commission on Antiepileptic Drugs 1998). The primary interest lies
in the contrast between immediate and deferred treatment, with possible in-
teractions with age, sex, pre-randomisation seizure type experienced and the
outcome of an electroencephalogram (EEG).
In studies of recurrent events, like epileptic seizures, there is frequently lots
of information about individuals' seizure patterns over a period of time that
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is generally not fully utilised in analysis. Additionally, epilepsy is charac-
terised by recurrent seizures, not a single, isolated event, yet in many treat-
ment studies it is often only time to rst seizure that is analysed. We develop
methodology that allows the pre-randomisation seizure counts and multiple
post-randomisation survival times to be jointly modelled. This method as-
sumes that all these outcomes are predicted by (unobserved) seizure rates.
We assume that each patient has an underlying constant seizure rate, which
we allow to vary depending on baseline attributes, and suppose that their
subsequent post-randomisation seizure rate will be reduced relative to their
associated baseline seizure rate. A greater reduction in the seizure rate results
in a longer time to seizure post-randomisation, indicating a better therapy.
The class of statistical models that will be developed consider some of the
issues arising when analysing data of this type. More specically, our data
exhibits cure rates and there is evidence to suggest that individuals' seizure
rates change not only at randomisation to treatment policy, but also following
a post-randomisation seizure.
As previously stated, we consider the development of new statistical method-
ology, which is applied to an epilepsy dataset. The methods developed in
this thesis, however, are not restricted to randomised controlled trials relating
to epilepsy. We consider novel statistical models that can be applied to any
recurrent event data that combine event counts and survival times.
2
1.1 Overview of Thesis
An overview of the current literature on count models and survival models
is provided in Chapter 2. The discussion of survival analysis includes non-
parametric, semi-parametric and fully parametric approaches to modelling.
Methods used to analyse data that is in the form of recurrent event gap times
are also presented. A complication in the analysis of survival data occurs when
there is a proportion of the population not susceptible to the event of inter-
est. When presented with data of this type cure rate models are appropriate.
These models are also discussed in Chapter 2, as is the existing literature on
a model that considers the analysis of a pre-randomisation event count and
a single post-randomisation survival time jointly. Finally, this chapter also
provides an overview of statistical analysis in the presence of missing data.
Chapter 3 provides an overview of epilepsy and introduces the dataset that
motivates the work in the thesis. Standard non-parametric analyses of the
data are also provided. We examine the clinical features of the individuals
included in the trial and generate Kaplan-Meier curves.
Standard parametric models are considered in Chapter 4. The event counts
and survival times are considered separately, with the Negative Binomial Gen-
eralised Linear Model being applied to the event counts. The Log-logistic
and Lomax survival distributions are considered for the analysis of the post-
randomisation times to rst seizure and times from rst to second seizure.
Chapter 5 develops a model for the joint analysis of pre-randomisation event
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counts and post-randomisation times to rst seizure and times from rst to sec-
ond seizure. The log-likelihood is derived, with the rst and second derivatives,
so that numerical methods can be applied to nd the maximum likelihood pa-
rameter estimates. This joint model is then applied to the dataset and the
results are interpreted in terms of pre-randomisation and post-randomisation
seizure rates.
Limitations to the simple joint model developed in Chapter 5 are considered
in Chapter 6. The simple joint model assumes that the post-randomisation
seizure rate remains constant, but a simple modication relaxes this assump-
tion. We also allow for the inclusion of cure rates for each of the survival times,
that is, we consider the scenario where individuals who enter the trial may be
immune to seizures post-randomisation. These two extensions are considered
both in isolation, and together in a single full model.
The performance of the nal full model is compared to standard survival meth-
ods in Chapter 7. We assess the goodness-of-t of the models, considering how
well the distribution of the survival times is modelled. We use a method devel-
oped by Maller and Zhou (1996) for testing the goodness-of-t of parametric
distributions to survival data.
Further extensions to the joint model are considered in Chapter 8. We consider
the appropriateness of the zero-truncated, one-inated Poisson distribution for
the count data and the inclusion of further post-randomisation survival times.
We discuss further possible analyses of the dataset that consider not only
the treatment policy to which an individual was randomised, but also which
4
antiepileptic drug they subsequently received. Finally, Chapter 8 also consid-
ers the analysis of long-term prognosis.
Chapter 9 concludes the thesis, discussing the strengths and weaknesses of
the various models that have been developed and the suitability of the under-
lying assumptions.
Appendix A contains detailed information on the Lomax survival distribu-
tion. The log-likelihood, rst derivatives and second derivatives are presented,
allowing inference on the parameters using numerical methods. Appendix B
contains the R functions used to t both the maximum likelihood simple joint
model that was initially developed and the nal full joint model that incorpo-
rates all the extensions considered. Finally, Appendix C contains a summary
of a clinical paper that is currently being written with neurologists at the
University of Liverpool. This paper considers the post-randomisation times
to rst seizure of any type and rst tonic-clonic seizure, using the joint model
that incorporates cure rates, that we have developed.
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Chapter 2
Literature Review
There is an abundance of literature that addresses the analysis of count data
and survival times separately. Some preliminary work has considered the
analysis of data where a recurrent event process is recorded in the form of
a pre-randomisation event count, followed by a post-randomisation time to
rst event, for each individual.
We shall present commonly used approaches for the analysis of event counts
and survival times and then outline methods that have been developed to
jointly analyse event counts and survival times in a single model.
We shall also present an introduction into missing data techniques. Likeli-
hood inference generally proceeds to derive the maximum likelihood estimate
of a parameter, , by maximising the observed likelihood. There might be two
problems with this: the observed likelihood could be impossible, or dicult
to derive due to the integration involved or, alternatively, it may be hard to
maximise. Methods used to handle missing data that focus on likelihood based
6
techniques can also be used when presented with problems of this type.
2.1 Analysis of Count Data
A model typically used for the analysis of count data is the Poisson Generalised
Linear Model (McCullagh and Nelder 1989). A restrictive property of the
Poisson distribution is that the mean and variance are equal. When presented
with count data that are overdispersed, random eect mixture distributions
are often used. The most convenient choice of random eects distribution
is the Gamma, which consequently yields the Negative Binomial distribution
(Greenwood and Yule 1920).
Alternatives to the Gamma distribution as the mixing distribution are consid-
ered by Hougaard et al. (1997), with special consideration being given to the
analysis of the frequency of epileptic seizures. A larger family of mixture dis-
tributions are considered, including the Inverse Gaussian mixture distribution.
This paper, however, does not consider the inclusion of covariates.
2.2 Analysis of Survival Data
Survival analysis is the analysis of data which is in the form of times from a
well dened start point, up to a particular event of interest. A comprehen-
sive and thorough discussion of survival techniques is given by Collett (2003).
The actual survival time, t, for an individual, is a realisation of the random
variable T , which can take any non-negative value. This random variable has
associated with it a probability distribution, with an underlying probability
7
density function f(t).
There are generally two functions that are of central interest in survival anal-
ysis, namely the survivor function and the hazard function. The survivor
function is dened to be the probability that an individuals' survival time is
greater than or equal to some value t, expressed as
S(t) = P(T  t) = 1  F (t); (2.1)
where F (t) is the cumulative distribution function of the random variable T .
The hazard function can be thought of as the instantaneous death rate. To
derive its form, rst consider the probability that an individuals' survival time
lies in the interval t and t + t, conditional on survival to time t, for some
 > 0. Dividing this probability by t then gives a probability per unit time.
The hazard function is simply the limiting value of this quantity, as t tends
to zero:
h(t) = lim
t!0

P(t  T  t+ t j T  t)
t

: (2.2)
A further function that may be of interest when considering survival data is
the cumulative hazard function, simply dened as
H(t) =
Z t
0
h(u)du: (2.3)
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2.2.1 Censoring
An important issue in survival analysis is that of censoring. Censoring occurs
when an individuals' actual survival time cannot be measured, but we have
instead some measurable censored time associated with them. There are gener-
ally three types of censoring: (i) right censoring, occurring when the censored
survival time is less than the actual, unknown survival time, (ii) left censor-
ing, occurring when the observed, censored survival time is greater than the
actual, unknown survival time, and (iii) interval censoring, which is evident if
the actual survival time is only known up to some interval. We consider the
analysis of data that is subject to right censoring.
The standard survival techniques outlined in this section are only applicable
if the censoring is non-informative. This essentially means that the censoring
is not related to any factors associated with the actual survival time.
2.2.2 Non-Parametric Procedures
Often the rst step in survival analysis would be to produce either graphical or
numerical summaries of the data based on non-parametric, or distribution-free
estimates of the survivor and hazard functions. These estimates are signicant
in their own right, but are generally used as a pre-cursor to more detailed anal-
ysis. The most widely used non-parametric estimate of the survivor function,
that allows for censoring, is the Kaplan-Meier estimate.
Given n individuals, let the number of individuals alive just before time t(j)
be denoted by nj, with dj denoting the number of deaths at this time. It
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follows that the estimated probability of survival through the interval t(j)   
to t(j), for small , is (nj dj)=nj. The probability of survival between t(j) and
t(j+1)  , the time immediately before the next death, is simply unity as there
are no deaths in this interval. The joint probability of surviving in the inter-
vals t(j)  to t(j) and t(j) to t(j+1)  is therefore estimated by (nj dj)=nj. It
follows that in the limit, as  tends to zero, (nj   dj)=nj becomes an estimate
of surviving from t(j) to t(j+1).
Now suppose that there are r death times, among the n individuals, that
are ordered t(1) < t(2) < : : : < t(r). The estimated survivor function at time
t, for t(k)  t < t(k+1) is simply the product of the probability of surviving
in the interval t(k) to t(k+1), and all preceding intervals. This leads to the
Kaplan-Meier estimate of the survivor function, given by
S^(t) =
kY
j=1
nj   dj
nj

; k = 1; 2; : : : r: (2.4)
2.2.3 Modelling Survival Data
In many situations, individuals' survival times will be accompanied by a num-
ber of explanatory variables, or covariates. Interest is most commonly con-
cerned with how one or more of these covariates may aect an individual's
survival time. When these situations arise, simple non-parametric approaches
are not sucient, and more sophisticated modelling is necessary. Many of
the principles and procedures of linear modelling lend themselves easily to the
modelling of survival data.
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Cox Proportional-Hazards Model
Probably the most widely adopted and well known of the survival models is
the Cox proportional-hazards model (Cox 1972). This is a semi-parametric
model, as it assumes that the hazard function for an individual is proportional
to some baseline hazard, but does not assume a probability distribution for
the survival times. We consider data that violates the proportional hazards as-
sumption, rendering the Cox model unsuitable. A brief discussion is included
here however, for completeness.
Consider a vector of m explanatory variables, x= (x1; x2; : : : ; xm), assumed to
have been collected at time zero, and let h0(t) be the baseline hazard function,
with x= (0; 0; : : : ; 0). Under the Cox proportional hazards model the hazard
function for the ith individual can then be written as
hi(t) = e
ih0(t);
where i =
0xi is the linear component of the model, also known as the risk
score or prognostic index, for the ith individual. Fitting the proportional
hazards model to a given data set involves estimating the coecients of the
explanatory variables, , and the baseline hazard, h0(t).
The Cox proportional hazards model is in many cases advantageous due to
its widespread applicability, owing to its lack of restriction to a specic func-
tional form. If, however, an assumed probability distribution is valid, infer-
ences from a fully parametric analysis will yield more precise results than the
Cox semi-parametric approach.
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Parametric Models
Superiority over the Cox proportional hazards model can be obtained through
parametric analysis, when the probability distribution assumed is accurate.
Preliminary study of the validity of a range of probability distributions can be
carried out using Kaplan-Meier estimates of the survival curves. Transform-
ing the survivor function to produce a plot that should give a straight line
if the assumed model is appropriate is one way of assessing the suitability of
parametric models. Common survival distributions include the Weibull, Ex-
ponential, Lognormal and Log-logistic distributions.
Assume that a suitable parametric model has been adopted, and that the
density function of the random variable associated with the survival times is
f(t). If there are no censored observations, then the likelihood for n observa-
tions is simply
Qn
i=1 f(ti). Now suppose that right censoring is present and
consider a censoring indicator, i, which takes the value zero if the ith survival
time, ti, i = 1; 2; : : : ; n is censored, and unity if the survival time is observed.
The likelihood is now given by
nY
i=1
ff(ti)gifS(ti)g1 i :
Parametric models can be categorised as proportional-hazards, proportional-
odds, accelerated failure time, or a combination of the three. Exploratory
analysis suggests that our data is best modelled through an accelerated failure
time model (Wei 1992), so we focus our attention on the family of distributions
satisfying this property. The accelerated failure time model assumes that for
individual i, the covariates act multiplicatively on the time scale, and so aect
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the rate at which individuals progress along time. If a distribution displays
the accelerated failure time property, the survivor function for individual i can
be expressed as
Si(t) = S0(t=e
i);
where S0(t) is the baseline survivor function. Common survival distributions
that are accelerated failure time are the Weibull, Exponential, Log-logistic,
Lognormal, Gamma, and Inverse Gaussian distributions.
Suitability of the accelerated failure time family of distributions is best as-
sessed using a Q-Q plot of the Kaplan-Meier estimate of the survivor func-
tions. If we consider the simple case where there are two groups, then the
accelerated failure time model says that S(t) in one group is equal to S(t)
in another. A plot of the percentiles of the Kaplan-Meier estimated survivor
curves should produce a straight line, with slope , that passes through the
origin if the accelerated failure time model is appropriate.
2.2.4 Recurrent Event Gap Times
Often, interest may lie in studying processes that generate events repeatedly
through time. Such processes are known as recurrent event processes and the
data they provide are referred to as recurrent event data (Cook and Lawless
2007). Typically, in medical settings there is recurrent event data available on
a large number of individuals, exhibiting a relatively small number of events.
Examples of such settings may include asthma attacks in respiratory studies or
epileptic seizures in neurology studies. Methods for handling recurrent event
data tend to be based on counts and rate functions, or the analysis of gap
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times, which we consider here.
We begin by considering the methodology currently available for renewal pro-
cesses. Renewal processes are ones in which the gap times between successive
events, Yj = Tj   Tj 1, (j = 1; 2; : : :), are independent and identically dis-
tributed. It is usually assumed that the time origin, t = 0, corresponds to
an event, but this may be relaxed to allow Y1 to have a dierent distribution
from (Y2; Y3; : : :). Cook and Lawless (2007) consider X(s; t), the number of
events over (s; t]. The distribution for counts, X(s; t), in renewal processes
is intractable except for the renewal process in which the Yj are exponential
random variables. That is, when the process is a homogeneous Poisson process.
Methods Based on Gap Times
Analyses based on gap times are often useful when events are relatively infre-
quent, when there is some type of renewal after an event, or when prediction
of the time to the next event is of interest.
We assume that individual i is observed over the time interval [0; i] and that
mi events are observed at times 0 < ti;1 < : : : < ti;mi < i, with yi;j = ti;j ti;j 1
and yi;mi+1 = i  ti;mi , where ti;0 = 0. The yi;j are the observed gap times for
individual i, with the nal time being possibly censored. The likelihood for n
individuals can be written in terms of the density and survivor functions:
nY
i=1
miY
j=1
f(yi;j)S(yi;mi+1): (2.5)
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If yi;mi+1 = 0, that is, if observation for individual i terminates after the mith
event, the term S(yi;mi+1) disappears.
2.2.5 Survival Analysis with Cure Rates
A proper survival distribution should have total mass 1, with the resulting
Kaplan-Meier curve having its asymptote at zero. That is, in standard sur-
vival analysis we assume that every individual in the sample is susceptible
to the event of interest. In some situations however, there may be a number
of individuals who would never experience the event of interest, regardless of
the time for which they were followed. Maller and Zhou (1996) encourage us
to think of these individuals as cured, or immune to the event of interest. If
survival data does indeed have a proportion that are immune to the event of
interest, considering a proper survival model that ignores this may give mis-
leading results. An improper survival distribution allows, formally, innite
survival times. Cure rate models allow the quantity p = F (1) = limt!1 F (t)
(where F (t) is the cumulative distribution function of the survival times) to
be strictly less than 1, corresponding to the presence of immunes in the pop-
ulation.
Suppose ti is the true survival time for individual i, which is only observed
if it does not exceed their associated censoring time, ci, otherwise we observe
ci. Consequently, the actual, observed survival time for individual i can be
expressed as ti = min(t

i ; ci). To formulate the probabilistic mechanism that
allows the true survival times ti to be innite rst assume that individual i
has an associated Bernoulli random variable, Bi, taking the value 1 if individ-
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ual i is susceptible to the event of interest, and with Bi = 0 corresponding
to an immune individual. Additionally, p < 1 represents the proportion of
susceptibles in the population, so that
Bi =
8><>: 1 with probability p;0 with probability 1  p:
In reality we do not know whether an individual is immune or not, so Bi is
not observed. Susceptible individuals are assumed to have a proper cumulative
distribution function, G(t), with G(1) = 1. Formally, individuals with Bi = 0
have ti =1, hence, for all t  0
Pfti  t j Bi = 1g = G(t);
Pfti  t j Bi = 0g = 0;
These probabilities imply that, for all t  0, the cumulative distribution func-
tion of the true survival times ti is
F (t) = Pfti  tg
= Pfti  t j Bi = 1gPfBi = 1g+ Pfti  t j Bi = 0gPfBi = 0g
= pG(t) + 0
= pG(t):
Consequently, for all t  0
G(t) =
F (t)
p
=
F (t)
F (1) : (2.6)
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To ensure that p remains within the interval [0; 1] the following reparameteri-
sation is often considered:
 = ln

p
1  p

:
We can also allow the cure rate to depend on individuals' covariates:
pi =
exp(0wi)
1 + exp(0wi)
:
The explanatory variables are entered into the covariate wi and the parameter
 is the corresponding vector of regression coecients.
2.3 Joint Modelling of Event Counts and a
Single Survival Time
Consider the case where for each individual we have a pre-randomisation event
count and a post-randomisation survival time. Most standard survival anal-
ysis may treat the pre-randomisation event count information as a covariate
(Verity et al. 1995); this strategy however ignores any existing variation be-
tween individuals. The pre-randomisation event count is an outcome in its own
right and Cowling et al. (2006) proposed a technique that jointly analysed an
individual's pre-randomisation seizure count, and a single post-randomisation
failure time under a Poisson process framework, in a single model.
We assume that each individual experiences events according to a Poisson
process with rate ii, where the parameter i relates to the baseline covari-
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ates, with additional heterogeneity in the population being modelled through
i, assumed to follow a Gamma distribution with expectation 1 and variance
1=. Smaller values of  are indicative of higher levels of heterogeneity. Con-
sequently, the pre-randomisation event count over a period ui, for individual
i, Xi, follows a Poisson distribution with mean iuii. If the underlying point
process is modelled through a Poisson process, then gap times between events
will be Exponential with the same rate. Consequently, post-randomisation, the
time to rst seizure will be Exponential, but the rate is updated to allow for a
treatment eect. It is assumed that the treatment eect acts multiplicatively
on the rate, so that the time to rst seizure for individual i post-randomisation,
Yi, is Exponential with event rate i ii, where  i depends on the treatment
in some way. In summary:
Xi j i  Poisson(iuii);
Yi j i  Exponential(i ii);
i  Gamma(; ):
Therefore the joint model is specied by the following equations:
fXj(xi j i;i; ui) = (iuii)
xi exp( iuii)
xi!
;
fY j(yi j i;i;  i) = i ii exp( i iiyi);
f(i;) =
 1i exp( i)
 ()
;
where i = exp(
0
1z1i) and  i = exp(
0
2z2i). The data enter the model through
z1i; z2i; ui; xi; yi and i, the censoring indicator taking the value zero if the time
to rst seizure post-randomisation is censored and unity if the survival time
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is observed. The baseline explanatory variables are entered into the covariate
z1i, and the treatment covariate z2i contains a treatment indicator, and may
also contain other explanatory variables and interaction terms. The parame-
ters 1 and 2 are the corresponding vectors of regression coecients.
If the random eect term is integrated out of the joint density of Xi and i,
then the resulting unconditional density, fX(xi;i; ui; ), is simply the Nega-
tive Binomial. The unconditional distribution of Yi, obtained when the random
eect term is integrated out of the joint density of Yi and i, is the Lomax
distribution (Johnson and Kotz 1970), with density
fY (yi;i;  i; ) =
Z 1
0
fY j(yi j i;i;  i)g(i;)di
=
i i
(1 + i iyi=)+1
: (2.7)
2.4 Missing Data
Standard statistical methods are well developed for the analysis of complete
rectangular data sets, where the the rows of a data matrix represent subjects.
Missing data arises when some of the observations in the data matrix are not
observed. One approach to handling missing data is to simply omit, from the
data matrix, those rows that contain missing values. This technique, com-
monly referred to as `complete-case analysis', although simple to carry out,
is generally inappropriate. The disadvantages of adopting this approach stem
from the potential loss of precision and induction of bias in discarding the
incomplete cases.
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A comprehensive discussion on statistical analysis in the presence of miss-
ing data is given by Little and Rubin (2002). They identify the problems
associated with the presence of missing data in standard statistical analysis,
consider how missingness can arise, present dierent missing data patterns and
discuss the various methods for handling datasets that exhibit missing data.
First we dene Y = (yij) to be the complete data matrix, and introduce
the missing data indicator matrix, M = (mij), which is unity if yij is missing,
and zero if yij is observed. Now the complete data Y can be partitioned into
Y = (Yobs; Ymis) where
Yobs = Y [mij = 0];
Ymis = Y [mij = 1]:
The full probability density function for the observed data, Yobs, missing data,
Ymis, and the missing data indicator, M , is f(Yobs; Ymis;M ; ; '). This full
probability density function can be factorised as:
f(Yobs; Ymis;M ; ; ') = f(Yobs; Ymis; )f(M j Yobs; Ymis;'); (; ') 2 
;';
(2.8)
where 
;' is the parameter space of (; '). The actual observed data con-
sists of the variables (Yobs;M), hence the probability density function for the
observed data can be obtained by integrating Ymis out of equation 2.8:
f(Yobs;M ; ; ') =
Z
f(Yobs; Ymis; )f(M j Yobs; Ymis;')dYmis: (2.9)
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Treating the missing data indicator as a random variable, the missing data
mechanism is characterised by f(M j Yobs; Ymis;'), the conditional distribu-
tion of M given (Yobs; Ymis), where ' denotes unknown parameters. The miss-
ing data mechanisms, more specically the question of whether the values that
are missing are related to the underlying variable values, are an extremely im-
portant issue in the area of missing data. Missing data mechanisms generally
determine how the missing data analysis should proceed. There are three dis-
tinct types of missing data mechanism: missing completely at random, missing
at random and not missing at random.
The missing data are said to be missing completely at random (MCAR) if
missingness does not depend on the values of Y , missing or observed. That is,
f(M j Yobs; Ymis;') = f(M ;'); for all Y; ': (2.10)
An assumption that is less restrictive than MCAR is missing at random
(MAR). If missingness depends on those values of Y that are observed, and
not on the components that are missing, the data are said to be MAR. That
is,
f(M j Yobs; Ymis;') = f(M j Yobs;'); for all Yobs; ': (2.11)
Finally if data is neither MAR or MCAR, that is the distribution ofM depends
on the missing values in the data matrix Y , we call the data not missing at
random (NMAR).
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2.4.1 Missing Data Methods
Methods proposed for handling missing data can be grouped into the following
categories:
Complete-Case Analysis: Analysis is carried out only on those cases for
which there is no missing data.
Weighting Procedures: A modication to complete-case analysis that dif-
ferentially assigns weights to the complete cases to adjust for bias. This
strategy is found most commonly in sample surveys to handle nonre-
spondents.
Imputation-Based Procedures: Essentially missing values are lled in, with
the subsequent completed data analysed using standard statistical meth-
ods. For the resulting inferences to be valid, modications to standard
analyses are necessary to allow for the diering status of the real and
imputed values.
Model-Based Procedures: A broad class of procedures can be generated by
dening a model for the observed data and basing subsequent inferences
on the likelihood or posterior distribution under that model.
We have already discussed the relative simplicity of discarding the incompletely
recorded units and the associated disadvantages. Complete-case analysis may
be justied, however, when the amount of missing data is small, so that the loss
of precision and bias is minimal. Weighted complete-case estimators are often
simple to compute, but the corresponding standard errors are less straightfor-
ward to derive.
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Imputation techniques are an attractive and exible method for handling miss-
ing data. However, one should be wary of the potential pitfalls. Users of
imputation methods should be considerate of the fact that the data are not
complete, and imputed values should not be regarded in the same way as real
values. Imputations are means or draws from a predictive distribution of the
missing values and so a method of creating a predictive distribution is required.
Modelling methods include, but are not limited to, mean modelling, regres-
sion modelling or last observation carried forward. Single imputation methods
replace missing values with a single imputed value, but multiple imputation
replaces missing values with a vector of D  2 imputed values. The D values
are ordered in such a way that D complete datasets are generated from the
vectors of imputations. Standard complete-data methods are used to analyse
each dataset, with the subsequent D complete-data inferences combined to
form one inference which reects the uncertainty due to nonresponse.
Likelihood based methods are more attractive than complete-case analysis or
imputation techniques (Schafer and Graham 2002). These methods, however
rely on a few crucial assumptions. The sample may have to be larger than
usual as missing data reduces the sample size and the sample needs to remain
large enough for the maximum likelihood estimates to be approximately un-
biased and normally distributed. Additionally, the likelihood function comes
from an assumed parametric distribution for the complete data and likelihood
methods may not necessarily be robust to deviations from the model assump-
tions.
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2.5 Discussion
This chapter has discussed the standard statistical models that currently exist
for the analysis of event counts and survival times. We have also outlined
models that can be used for the analysis of survival data when there are cure
rates present in the population and models that can be used in the analysis of
recurrent events.
Cook and Lawless (2007) discuss the use of models that are appropriate in
the specication and testing of treatment eects in recurrent events (x 8.4.1).
They suggest that methods based on rates and mean functions, rather than
gap times, oer the most straightforward specication of treatment eects for
recurrent events and outline the mixed Poisson model as a natural framework
for analyses. Although methods based on rates and mean functions may be
the most advantageous for the specication and testing of treatment eects in
recurrent events, Cook and Lawless (2007) recognise that there may be situ-
ations where analyses based on gap times are more natural. Additionally, if
datasets exhibit cure rates, models that focus on rates and mean functions are
not the most conclusive. Such models would assess post-randomisation event
rates that are zero, but to consider this, focus would need to be on a suitable
length of observation time, or gap time, with no events recorded.
An additional consideration in the analysis of recurrent event data, that is
considered by Cook and Lawless (2007) in x 8.4.3, is the use of baseline
count data. Interest is focussed on the use of mixed Poisson processes for
the analysis of recurrent event data that incorporates a period of observation
24
in which subjects are monitored prior to randomisation to treatment. Interest
in this instance would be focussed on the change in event rate pre and post-
randomisation. There is no discussion, however, of the analysis of recurrent
event data that arrive in the form of a pre-randomisation baseline count and
post-randomisation gap times. Recall that time to rst seizure is an interna-
tionally agreed outcome in epilepsy trials (ILAE Commission on Antiepileptic
Drugs 1998), so methods pertaining to the analysis of gap times, that fully
make use of the pre-randomisation event counts, seem the most sensible.
A model that considers the analysis of pre-randomisation event counts and
a single post-randomisation survival time, proposed by Cowling et al. (2006),
has been discussed in this chapter. It is suggested that these methods may
form the basis of a model that allows pre-randomisation event counts and mul-
tiple post-randomisation survival times to be jointly analysed in a single model.
Finally, this chapter has briey presented missing data methods that are com-
monly adopted when presented with incomplete data. The dierent missing
data mechanisms and methods for handling missing data have been discussed.
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Chapter 3
Introduction to the Epilepsy
Data
We shall now present an overview of epilepsy and introduce the dataset that
will be analysed using both standard statistical methods and the new joint
models that we shall develop in later chapters. We shall conduct exploratory
analysis on the data and produce a number of Kaplan-Meier plots that will
form an initial examination of the eect of the explanatory variables on times
to rst and second seizure.
3.1 Overview
Epilepsy is formally dened as the occurrence of recurrent and unprovoked
seizures (Warrell et al. 2003). An epileptic seizure itself is caused by excessive
neuronal activity which will manifest itself in an alteration of consciousness,
or motor, sensory, autonomic, or psychic events. The International League
Against Epilepsy (ILAE) classication scheme divides seizures into partial,
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generalised or unclassied seizures (Berg et al. 2010). Partial seizures are
localised and involve only part of the brain; they can be either simple (con-
sciousness not impaired) or complex (consciousness impaired).
Partial seizures include motor, sensory, occipital, frontal lobe and temporal
lobe seizures. Motor seizures focally aect parts of the body that are corre-
lated with their area of representation in the motor cortex. Following motor
seizures there can be (on rare occasions) paralysis of the aected part. Sen-
sory seizures comprise paraesthesias or numbness in focal areas of the body.
Symptoms of occipital seizures are visual, altering the size, shape or depth of
objects. Jerking or forced closure of the eyelids may also occur. Frontal lobe
seizures are composed of pelvic thrusting, rocking of the body and head move-
ments that are nocturnal. Vocalisation may also occur. Suerers of temporal
lobe seizures may sense a loss of personal or environmental reality and can ex-
perience intense familiarity or unfamiliarity, psychic symptoms and sensations
pertaining to smell, taste and vertigo.
Partial epilepsy can sometimes occur with secondary generalisation. Gener-
alised seizures involve all of the brain and are categorised as tonic-clonic (grand
mal epilepsy), absence (petit mal epilepsy), myoclonic or atonic. Tonic-clonic
seizures consist of a tonic phase where an individual becomes sti as muscles
contract, and a clonic phase where limbs jerk caused by the muscles contract-
ing and relaxing in quick succession. During absence seizures, activity ceases
and individuals simply stare blankly and are unresponsive, without loss of
posture. Patients are totally unaware of their absence seizures. Symptoms of
myoclonic seizures are brief, shock-like contractions of muscles, which may be
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generalised or focal. Atonic seizures comprise a sudden loss of muscle tone;
episodes are brief and recovery rapid.
Epilepsy can be genetically determined, caused by migration disorders or
trauma. Epilepsy syndromes, such as juvenile myoclonic epilepsy, usually
occurring between the ages of 12 and 18, are inherited. A certain proportion
of children who suer epilepsy syndromes will go on to develop epilepsy at a
later age. Epilepsy can also be linked with the presence of tumours, incidence
of strokes, infection, cerebral degeneration, multiple sclerosis or metabolic dis-
orders. Epileptic seizures can be encouraged by lack of adequate sleep, alcohol
abuse and the ingestion of certain drugs; seizures may also be conned to the
menstrual period. Epilepsy attacks can additionally be triggered by particular
stimuli, such as noise and movement.
The question of whether to start patients on a course of anticonvulsants after
a single epileptic seizure remains an area of uncertainty. Several studies have
shown that intervention after a single seizure reduces the risk of short-term
recurrence, but does not aect the long-term remission rates in individuals
with single or infrequent seizures (Marson et al. 2005; Chandra 1992). War-
rell et al. (2003) state that seizure recurrence after a single untreated seizure
is around 80%, but Berg and Shinnar (1991) put seizure recurrence at 50%.
It is suspected that seizure recurrence may be dierent for dierent seizure
types, which may account for the dierence in these two values. It is also
thought that the risk of future seizures increases with the number of previous
seizures, with around 30% of epilepsy suerers never achieving long-term re-
mission (Cockerell et al. 1995).
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Antiepileptic drugs (AEDs) often come with extremely unpleasant side eects,
which include weight loss or weight gain, altered mood, drowsiness, hair loss,
polycystic ovarian disease, visual eld defects and teratogenicity. For most
epilepsy suerers, the benets of AEDs will far outweigh the associated risks.
For those individuals, however, who have had only a single seizure, or have
infrequent and mild epileptic seizures the question of whether to withhold
treatment until absolutely necessary becomes clinically important.
Typically, the questions asked by individuals in early epilepsy might be: `If
I have a seizure, am I likely to have another one, and if so, when?' or `If
I have a second seizure am I likely to have more, and with increased fre-
quency?'. We aim to develop methodology that attempts to provide answers
to these questions and ascertains how these questions might be dependent
on important covariates such as seizure type or EEG outcome. We have al-
ready presented some of the existing literature for the analysis of recurrent
event data. This work would encourage us to think of epileptic seizures in
terms of counts, possibly comparing the dierence in counts pre and post-
randomisation. Clearly, when presented with questions of this type it is more
natural, and clinically relevant, to analyse recurrent event data in terms of
the survival times. Additionally, recall that time to rst seizure is an inter-
nationally agreed outcome (ILAE Commission on Antiepileptic Drugs 1998)
in epilepsy trials. Standard methodology exists for the analysis of recurrent
survival data, but, as we have previously discussed, there is no literature that
provides a parametric modelling strategy for pre-randomisation event counts
and multiple post-randomisation survival times.
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3.1.1 The MESS Trial
The MRC Multicentre Trial for Early Epilepsy and Single Seizures (MESS)
was undertaken to address the question of immediate versus deferred treat-
ment with AEDs in those patients that have had one, or very few seizures.
Interest lay in both the eects on short-term recurrence, and long term prog-
nosis.
The MESS trial randomised 1443 patients worldwide, across 83 centres. The
eligibility criteria were: being aged at least 1 month, having a suitably docu-
mented history of at least one clinically denite, spontaneous and unprovoked
epileptic seizure (excluding febrile convulsions), and there being genuine uncer-
tainty in both clinician and patient as to whether treatment with AEDs should
commence. Patients were excluded from the trial if they had previously re-
ceived treatment with AEDs. Patients were randomised to either immediate
or deferred treatment using the minimisation method, balancing across two
factors: centre or region, and number of seizures prior to randomisation (de-
ned as either single or multiple).
The trial was a pragmatic trial, meaning that those individuals assigned to im-
mediate treatment were administered the most appropriate antiepileptic drug,
determined by the clinician. Those patients randomised to deferred treatment
received no drugs until both clinician and patient agreed that treatment was
absolutely necessary, in which case the clinician decided the optimum anticon-
vulsant, dose and duration of treatment.
30
Baseline covariates collected for each individual included age, sex, demographic
information, any history of existing neurological disorders and information on
past seizures including the number of seizures experienced and seizure type.
An electroencephalogram (EEG) was requested for each individual, CT and
MRI scans were performed if clinically indicated. Follow-up occurred at 3
months, 6 months, 1 year, and then at yearly intervals (more regularly if
clinically necessary). At each follow-up information was collected about any
seizures the patient had experienced since the previous follow-up, along with
information about AEDs currently being taken, including dose and any side-
eects experienced. In the event of death, the date and cause of death were
recorded. The outcomes measured included times to rst, second and fth
seizure, as well as times to one and two year remission.
Recruitment for the trial ran from 1st January 1993 to 31st December 2000. Fi-
nal follow-up was attempted between 31st December 2001 and 30th June 2002.
Statistical analyses were by intention to treat, interest lay in the treatment
policy to which an individual was assigned rather than whether an individual
was receiving treatment or not when they experienced future seizures. De-
tailed methods and primary analyses can be found in Marson et al. (2005)
and Kim et al. (2006). We shall present a brief summary of each of the trials
here.
To analyse the times to each outcome event, Marson et al. (2005) used the
log-rank test (Peto and Peto 1972), or the Cox proportional-hazards model
when adjusting for the number of seizures pre-randomisation. The number of
seizures pre-randomisation was taken to either be single or multiple. The key
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demographic and clinical features of participants are given in Marson et al.
(2005), including the number of individuals experiencing particular types of
seizures pre-randomisation, stratied by the treatment policy to which they
were subsequently assigned. Also included is the number of individuals pre-
senting an abnormal EEG and whether the abnormalities were non-specic,
generalised or focal. This analysis of the MESS data does not consider pre-
randomisation seizure types, or EEG outcome, in the analysis of the post-
randomisation times to events of interest. For times to rst seizure and times
to second seizure the dierences between the two treatment groups were found
to be statistically signicantly dierent (2 = 21:4, p< 0:0001 and 2 = 9:2,
p= 0:0025 respectively).
Kim et al. (2006) developed a prognostic model to categorise individuals as
low risk, medium risk or high risk of seizure recurrence, using Cox regression,
stratied by treatment policy. For the prognostic model, the number of groups
likely to maintain reasonable separation was found to be three. In this analy-
sis of the MESS data, EEG outcome and pre-randomisation seizure type were
considered. The seizure types considered were `tonic-clonic seizures only' and
`simple or complex partial seizures only'. An abnormal EEG was dened as
a focal or general, excluding non-specic abnormalities. Backwards stepwise
regression was used and found three potentially important prognostic factors:
existence of a neurological disorder, total number of seizures pre-randomisation
over all seizure types and an abnormal EEG. Seizure type pre-randomisation
was not found to be signicant for the prognostic model.
The statistically signicant prognostic factors were used to identify individuals
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as at a low risk, medium risk or high risk of seizure recurrence as follows:
 Low risk - one seizure only pre-randomisation, no neurological disorder
and a normal EEG.
 Medium risk - two or three seizures pre-randomisation, no neurological
disorder and a normal EEG; or one seizure pre-randomisation and either
a neurological disorder, or an abnormal EEG.
 High risk - one seizure pre-randomisation, a neurological disorder and an
abnormal EEG; or two or three seizures pre-randomisation and either a
neurological disorder, or an abnormal EEG, or both; or any individual
with 4 or more seizures pre-randomisation.
For low-risk individuals, there was no signicant dierence found between the
treatment policies. For individuals in the medium and high risk groups, im-
mediate treatment was favoured when considering seizure recurrence.
We carry out exploratory analysis on 1425 individuals; 18 were removed due to
missing information, assumed missing completely at random. It is important
to note that 812 of the 1425 individuals included in the exploratory analysis
presented only a single seizure pre-randomisation. The period of time from this
single seizure to randomisation, for these individuals, ranged from the same
day to 464 days, with the median number of days being 27. For the majority
of those individuals with only one seizure pre-randomisation, their associated
period of time from rst seizure to randomisation may be inaccurately small,
possibly representing how long it took for them to arrange an appointment
with their GP. This results in imprecise estimates of their associated underly-
ing seizure rates and an ensuing overestimation of the seizure rate reductions.
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Following discussions with clinicians, we subsequently made adjustments to
the values of ui, the number of days from the rst pre-randomisation seizure
to randomisation, in the dataset so that ui  182. That is, any value of
ui < 182, we replaced with 182.
As a sensitivity analysis to the choice of 182 days as the minimum period
pre-randomisation, the data were re-analysed with ui  91 and ui  365. The
resulting regression coecients from these adjustments can be found in Rogers
et al. (2009), along with their associated bi and b i. The magnitudes of dier-
ences observed in seizure rates between the groups were maintained through
each adjustment.
The log-likelihoods associated with each model would suggest that having a
minimum pre-randomisation period of 365 days is optimal. Further inspection
of the log-likelihoods however, suggested that the likelihood function is very
at, hence the decision was made to take the clinicians' suggestion of a mini-
mum pre-randomisation period of 182 days. All future analysis of the MESS
data will be carried out with this adjustment.
3.2 Distribution of Variables
Of the 1425 individuals included in the exploratory analysis, 691 (48:91%)
experienced at least one seizure following randomisation, with a subsequent
480 (69:46%) of these experiencing a second. Later ndings conclude that
the variables age and sex are not statistically signicant in determining pre-
randomisation seizure rates or post-randomisation seizure rate reductions, so
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we exclude these variables completely here. EEG outcome is simply dened
as being abnormal or normal; further investigation concluded that there was
no statistically signicant dierences between the eects of the various types
of EEG abnormality on post-randomisation survival times (2 = 2, p= 0:569),
only the presence of a normal EEG or abnormal EEG of any type was found
to be statistically signicant. The pre-randomisation seizure types are cate-
gorised as follows:
Tonic-Clonic: Those individuals presenting with tonic-clonic seizures only
pre-randomisation.
2 Tonic-Clonic: Those individuals presenting with partial seizures with sec-
ondary tonic-clonic seizures pre-randomisation.
Generalised: Those individuals presenting with any combination of gener-
alised seizures pre-randomisation (this group could include those having
a combination of tonic-clonic and other generalised seizures).
Partial: Those presenting with partial seizures only pre-randomisation (either
simple or complex).
Other: Those presenting with seizures pre-randomisation that do not t into
any of the above categories.
Immediate treatment reduces the risk of a seizure post-randomisation (one
year relative risk 0.734 [95% C.I. (0.63,0.85)], 8 year relative risk 0.820 [95%
C.I. (0.74,0.91)]). Additionally, having an abnormal EEG will increase the risk
of seizure recurrence (one year relative risk 1.325 [95% C.I. (1.15,1.53)], 8 year
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relative risk 1.302 [95% C.I. (1.17,1.45)]). For those who have a seizure post-
randomisation, neither treatment policy nor EEG outcome are statistically
signicant in determining the risk of experiencing a second post-randomisation
seizure.
Table 3.1 shows the clinical features for the 1425 individuals included in the
exploratory analysis. Over half of the sample experienced tonic-clonic seizures
only pre-randomisation (54.8%) and almost a third experienced tonic-clonic
seizures with partial seizures (31.9%). Just 7.2% of those randomised had
only partial seizures pre-randomisation, with the other seizure groups making
up the remaining 6.1%.
Those with tonic-clonic seizures only and tonic-clonic seizures with partial
seizures have statistically signicantly lower abnormal EEG outcomes than
those with partial seizures only pre-randomisation.
By examining the percentages with one and two seizures at dierent points in
time, we can see that numbers appear to be levelling o. The fact that these
gures seem to be levelling o suggests that those individuals susceptible to
rst and second seizures post-randomisation have presented with these seizures
by 8 years. These gures also fall well below 100%, suggesting that there may
be a cure fraction in the population, that is, not everyone is susceptible to
seizures post-randomisation.
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3.3 Nonparametric Estimation of Gap Time
Distributions in the Analysis of Recurrent
Event Data
When data consists of repetitions of the same event through time, there are
essentially two possible time scales that may be of interest: the total time,
measured from the start of the follow-up, to the occurrence of all the events,
or the gap times, that is, the durations between two successive events. Analysis
of the MESS data focusses on the analysis of the times from randomisation to
rst seizure, and the times from rst to second seizure, with the overall follow-
up time subject to right censoring. When dealing with gap time distributions
of recurrent events in this censoring scenario, all the gap times, except the rst
one, may be subject to dependent censoring (Lin et al. 1999). We consider
data where the duration of the time to rst seizure will have an eect on the
potential censoring value of the second duration. A long time to rst seizure
post-randomisation implies a short observation period for the time from rst
to second seizure post-randomisation, and vice versa.
Recall that when examining the percentages of individuals with rst and sec-
ond seizures at dierent points in time post-randomisation, in Table 3.1, we
observed a levelling o of gures. It was proposed that this levelling o sug-
gested that everyone susceptible to two seizures post-randomisation had pre-
sented with both by 8 years. This result subsequently means that dependent
censoring may not be an issue in the analysis of this dataset. It would appear
that the individuals are followed up for the required amount of time such that
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a long time to rst seizure will not bear on the observation period for the time
from rst to second seizure.
Let T1i and T2i be the time to rst and second seizure respectively, for in-
dividual i, i = 1 : : : n. Now set Y1i = T1i and Y2i = T2i   T1i, so that Y1i is
the actual time to rst seizure and Y2i is the actual time from rst seizure to
the second. Nonparametric estimation of the marginal gap time distributions
can be dicult, but Visser (1996) proposes a nonparametric estimator of the
conditional survivor function of Y2 j Y1. First recall that we are considering
data where the censoring mechanism bears on the sum of the times to rst
and second seizure, rather than on each time separately. Suppose that Y 1 and
Y 2 are the random variables associated with the true gap times. The observed
random variables are therefore
Y1 = min(Y

1 ; C); Y2 = min(Y

2 ; C   Y 1 )I(Y 1  C);
where I(A) is the indicator function of the event A and the random variable C
represents the censoring time. The observed random variables, for n individ-
uals, are (Y1i; Y2i; i), i = 1; : : : ; n, where  is the censoring indicator, taking
the values
 =
8>>>><>>>>:
1; if C < Y 1 ;
2; if Y 1  C < Y 1 + Y 2 ;
3; if Y 1 + Y

2  C:
Visser (1996) assumes that (Y 1 ; Y

2 ; C) are discrete random variables and that
they take values in (0; 1; 2; : : : ; K). It follows that Y1 and Y2 are also discrete
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random variables, taking values in (0; 1; 2; : : : ; K). They denote the bivariate
survivor function of the pair (Y1; Y2) by SY1;Y2(k; l) = P(Y1  k; Y2  l). Addi-
tionally, let SY1(k) = P(Y1  k) and SY2jY1(l j k) = P(Y2  l j Y1  k) denote
the survivor function of Y1 and the conditional survivor function of Y2 given
that Y1  k respectively.
In addition to the survivor functions, Visser (1996) denotes the hazard func-
tion of Y1 and the conditional hazard function of Y2 given that Y1  k by
hY1(k) = P(Y1 = k j Y1  k) and hY2jY1(l j k) = P(Y2 = l j Y1  k; Y2  l)
respectively. It is straightforward to evaluate the subsequent survivor function
of Y1, using the associated hazard function:
SY1(k) = f1  hY1(0)g : : : f1  hY1(k  1)g; k = 1; 2; : : : ; K; SY1(0) = 1: (3.1)
The conditional survivor function and conditional hazard function of Y2 given
that Y1  k are related in a similar way.
The estimator of the conditional hazard function of Y2 given that Y1  k,
proposed by Visser (1996), is given by
ehY2jY1(l j k) = nX
i=1
I(Y1i  k; Y2i = l; i = 3)
 nX
i=1
I(Y1i  k; Y2i  l)
 1
:
(3.2)
This estimator is in general a biased estimator for hY2jY1(l j k), except when
k = K, or when Y1 and Y2 are independent. Substituting this estimator
into the expression relating the conditional hazard function to the conditional
survivor function would result in inconsistent estimates of SY2jY1(l j k). Instead
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Visser (1996) considers the estimators of hY1(k) and hY2jY1=k(l) = P(Y2 = l j
Y1 = k; Y2  l), given by
bhY1(k) = nX
i=1
I(Y1i = k; i  2)
 nX
i=1
I(Y1i  k)
 1
; (3.3)
bhY2jY1=k(l) = nX
i=1
I(Y1i = k; Y2i = l; i = 3)
 nX
i=1
I(Y1i = k; Y2i  l)
 1
:(3.4)
It is then straightforward to obtain estimators, bSY1(k) and bSY2jY1=k(l), of the
survivor functions of Y1, and Y2 given that Y1 = k respectively. The subsequent
estimator of SY2jY1(l j k), proposed by Visser (1996), is based on the following
transformation:
SY2jY1(l j k) = fSY1(k)g 1
KX
j=k
SY2jY1=j(l)fSY1(j)  SY1(j   1)g: (3.5)
We can determine the severity of the dependent censoring in our data set
by comparing estimates of SY2jY1(l j k) with Kaplan-Meier estimates of the
marginal survivor function for Y2.
Figure 3.1 shows the estimates of SY2jY1(l j k) plotted against the corresponding
Kaplan-Meier estimates of the marginal survivor function for Y2. We can see
that in general Kaplan-Meier estimates of the survivor function are lower than
the conditional estimates of the survivor function. We have already discussed
that underestimates of survival may be due to the fact that a longer time
to rst seizure, results in a shorter subsequent observation period for second
seizure. This consequently means that more observations may be censored,
which would lead to underestimates in survival probabilities.
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Figure 3.1: Estimates of SY2jY1(l j k) plotted against the corresponding uncon-
ditional marginal Kaplan-Meier estimates.
Cook and Lawless (2007) address the issue of dependent censoring and sug-
gests ways to facilitate the examination of marginal gap time distributions.
One approach is to t random eects models, which use individual-specic
independent and identically distributed random eects to induce associations
among gap times. Such models assume that given a random eect, the gap
times for an individual are independent. This is the approach that we shall be
considering in our modelling strategy. Other methods considered are the spec-
ication of a multivariate model for a specied set of gap times or conditional
models.
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3.3.1 Kaplan-Meier Plots
We consider Kaplan-Meier plots of the outcomes time to rst seizure and time
from rst seizure to second, examining possible treatment policy, EEG out-
come and seizure type eects.
The Kaplan-Meier curves in Figure 3.2 highlight immediately that treatment
policy appears to be inuential in determining an individual's time to rst
seizure post-randomisation, but not their time from rst to second seizure. A
plausible explanation for this is that those individuals randomised to deferred
treatment who experience a seizure post-randomisation would most likely re-
ceive subsequent treatment with AEDs, bringing them in line with those allo-
cated to immediate treatment thereafter.
Note that the each of the Kaplan-Meier curves in Figure 3.2 have their asymp-
totes well above zero. This suggests that the associated survivor functions
may not be proper and that there may be a proportion of the individuals' in-
cluded in the MESS trial `immune' from seizure recurrence post-randomisation.
These cure rates are apparent for those allocated to immediate and deferred
treatment.
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Figure 3.2: Kaplan-Meier curves for time to rst seizure and time from rst
to second seizure (with 95% CI), stratied by treatment policy.
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Figure 3.3: Empirical cumulative distribution function for Y1=T2.
Figure 3.3 shows the empirical cumulative distribution function for Y1=T2.
Note that this is only considered for those individuals presenting at least two
seizures post-randomisation, as there is evidence to suggest that dependent
censoring is present. We observe that this plot has its median at 0:663, sug-
gesting that for those experiencing at least two seizures post-randomisation,
their time from rst seizure to second is typically shorter than their time
from randomisation to rst seizure. Around 60% of those having at least two
seizures post-randomisation have Y1 > Y2, with approximately 30% having Y1
around nine times bigger than Y2. These results suggest that there may be
clustering within seizures.
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Figure 3.4 shows that those individuals presenting with generalised or par-
tial seizures pre-randomisation typically have a shorter time to rst seizure
post-randomisation than the other seizure types. Those individuals with
generalised seizures pre-randomisation also present their second seizure post-
randomisation much sooner than other seizure types. Additionally, the dier-
ences between the Kaplan-Meier curves appear to be more pronounced for the
second seizure post-randomisation, than for time to rst seizure.
Figure 3.5 suggests that for those participants presenting with partial seizures
only pre-randomisation, treatment policy appears to have no eect on their
time to rst seizure post-randomisation. For all other seizure types immediate
treatment is favoured.
When considering EEG outcome, Figure 3.6 indicates that for those presenting
a normal EEG, treatment policy has no eect on their associated time to rst
seizure. For those with an abnormal EEG, allocation to immediate treatment
brings their expected time to rst seizure in line with those having a normal
EEG. Those randomised to deferred treatment, following an abnormal EEG
outcome can expect a much shorter time to rst seizure post-randomisation.
For time from rst to second seizure post-randomisation there appears to be
no dierence in the four Kaplan-Meier curves.
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Figure 3.4: Kaplan-Meier curves for time to rst seizure and time from rst
to second seizure, stratied by seizure type pre-randomisation.
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Figure 3.5: Kaplan-Meier curves for time to rst seizure and time from rst
to second seizure, stratied by seizure type pre-randomisation and treatment
policy.
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Figure 3.6: Kaplan-Meier curves for time to rst seizure and time from rst
to second seizure, stratied by EEG outcome and treatment policy.
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Finally, Figure 3.7 gives an indication as to any interactions between EEG out-
come and pre-randomisation seizure types that may be present. For time to
rst seizure, EEG outcome appears to be inuential for those with secondary
tonic-clonic seizures pre-randomisation, with those having a normal EEG far-
ing better. EEG outcome also seems to have a slight impact on time to rst
seizure for those with tonic-clonic seizures only pre-randomisation, and possi-
bly for those with generalised seizures pre-randomisation. These interactions
are not seen for time from rst to second seizure.
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Figure 3.7: Kaplan-Meier curves for time to rst seizure and time from rst to
second seizure, stratied by seizure type pre-randomisation and EEG outcome.
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Transformations of the Kaplan-Meier curves can indicate which parametric
distributions may be most suitable for formal statistical modelling of survival
data. Transforming the Kaplan-Meier estimate of the survivor function to
produce a plot that should give a straight line if the assumed model is ap-
propriate is one way of assessing the suitability of parametric models. The
survivor function of the Log-logistic distribution with shape parameter  and
scale 1= is given by:
S(y) = f1 + (y)g 1: (3.6)
From Equation 3.6, the log-odds of survival beyond y can be expressed as:
ln

S(y)
1  S(y)

=   ln   ln y: (3.7)
It follows from Equation 3.7 that if the the survivor function is estimated using
the Kaplan-Meier estimate, and the subsequent estimated log-odds of survival
beyond y are plotted against log(y), a straight line with intercept   ln and
slope   will be observed if the Log-logistic distribution is appropriate.
Figure 3.8 shows the estimated log-odds of survival beyond y plotted against
ln(y) for times to rst seizure and from rst to second seizure. We observe
that both of these plots are straight lines, which supports the suitability of the
Log-logistic distribution in the parametric modelling of the MESS data.
Recall that the Log-logistic distribution belongs to the accelerated failure time
family of distributions.
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Figure 3.8: Log-odds of Kaplan-Meier estimates of survival for time to rst
seizure and time from rst to second seizure, stratied by seizure type pre-
randomisation and EEG outcome.
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3.4 Discussion
The MESS data contains information on 1443 patients, randomised to either
immediate or deferred treatment. The MESS trial was a pragmatic trial, so
that individuals received the optimal type and dose of AED, as determined by
the clinician.
Exploratory analysis of the MESS data was carried out on 1425 individu-
als. There were 18 individuals with missing information, assumed missing
completely at random, excluded from the analyses. Previous analyses of the
data have concluded that treatment policy is statistically signicant in de-
termining times to rst and second seizure, but this analysis did not include
information available on seizure types and used a log-rank test, or the Cox
proportional-hazards model (Marson et al. 2005), despite the data violating
the proportional-hazards assumption. An alternative analysis of this data de-
veloped a prognostic model based on the existence of a neurological disorder,
total number of seizures experienced pre-randomisation and the presence of an
abnormal EEG (Kim et al. 2006). The prognostic model was used to categorise
individuals as at a low risk, medium risk or high risk of seizure recurrence. For
those at a low risk, there was no statistically signicant dierence in treatment
policy on times to rst seizure post-randomisation. For those determined as
medium or high risk, immediate treatment was favoured.
Non-parametric estimates of the Kaplan-Meier curves are presented in this
chapter to provide an initial indication as to possible covariate eects that
may exist. Treatment policy seems to be signicant overall in determining
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times to rst seizure post-randomisation, but not times from rst to second
seizure. We also note that there may be cure rates present in the data. For
those who have at least two seizures post-randomisation, their time from rst
to second seizure is typically shorter than their time to rst seizure, suggesting
that clustering within seizures may be present.
Our analysis of the MESS data takes into consideration the types of seizures
an individual has experienced pre-randomisation. The corresponding Kaplan-
Meier curves suggest that seizure type may be signicant in determining times
to rst and from rst to second seizure. Additionally, there is evidence to
suggest that there may be seizure type interactions with treatment policy and
EEG outcome, on post-randomisation survival times. A strong interaction
between EEG outcome and treatment policy has also been observed for time
to rst seizure post-randomisation.
When basing the analysis of recurrent event data on gap times, an important
issue that must be addressed is that of dependent censoring. The marginal
Kaplan-Meier estimates of the survival function, for the times from rst to
second seizure, have been compared with conditional estimates of the survivor
function of Y2 j Y1, proposed by Visser (1996), to determine the severity of the
eect of dependent censoring in this dataset. Methods used to conduct gap
time analysis in recurrent event data, when dependent censoring is present,
have been discussed.
Following the non-parametric, exploratory analysis of the MESS data that
has been carried out in this chapter, we shall rst formally analyse each of the
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outcomes separately, using standard statistical techniques. In later chapters
we shall analyse the pre-randomisation event counts and post-randomisation
survival time jointly, in a single model.
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Chapter 4
Univariate Analysis of the Event
Counts and Survival Times
We shall begin by considering the univariate analysis of the pre-randomisation
counts, using standard statistical techniques. We shall then go on to analyse
each of the post-randomisation survival times separately, using two standard
survival distributions. We shall comment on the statistical signicance of the
covariates and compare the two survival distributions.
Note that there were ve of the 1425 individuals considered in the exploratory
analysis with incomplete information on their associated seizure history. These
individuals were excluded from the formal statistical modelling. Additionally,
Table 3.1 showed that only 3.4% and 2.7% of those randomised experienced
either generalised seizures or other seizures respectively pre-randomisation.
These groups are suciently small that any statistically signicant covariate
eects associated with these seizure type groups are unlikely to be conrmed
in subsequent statistical modelling. The decision was made to also exclude
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these individuals from nal analyses. This left us with a nal sample size of
1334.
4.1 Analysis of Pre-Randomisation Counts
We consider the Negative Binomial Generalised Linear Model as a marginal
model for the pre-randomisation event counts, specied by the following prob-
ability density function:
fX(xi;i; ui; ) =
 (xi + )
xi! ()

iui
+ iui
xi 
+ iui

; (4.1)
where i = exp(
0
1z1i). Here z1i is a vector of covariates for individual i, and
1 is a vector of regression coecients, including an intercept term.
All analyses in this thesis have been carried out in R. The estimated regression
coecients for the Negative-Binomial marginal count model are given in Ta-
ble 4.1. The small value of  suggests that there is substantial heterogeneity
within the population. A regression coecient > 0 (< 0) would indicate an
increased (decreased) seizure count relative to the seizure count in the refer-
ence group, which contains those individuals presenting with partial seizures
only pre-randomisation.
Examination of the coecients in Table 4.1 tells us that individuals with tonic-
clonic seizures only and secondary tonic-clonic seizures pre-randomisation have
statistically signicantly lower pre-randomisation seizure rates than those in-
dividuals presenting with partial seizures only pre-randomisation.
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Regression Estimates (standard errors) for
Coecient Negative Binomial GLM
 2.088 (0.113)
1;0 -4.119 (0.084)
1;t c -1.086 (0.093)
1;2t c -0.686 (0.095)
1;partial reference
-Log-likelihood (d.f.) 2486 (1330)
Table 4.1: Estimated regression coecients for the Negative Binomial GLM.
tonic-clonic.
4.2 Analysis of Post-Randomisation Survival
Times
Recall from Figure 3.8 that transformations of the Kaplan-Meier estimates of
the survivor function suggested that the survival data may be well modelled
through the Log-logistic distribution, which belongs to the accelerated fail-
ure time family of distributions. Additionally, recall that in the joint model,
developed by Cowling et al. (2006), the unconditional distribution of the
post-randomisation times to rst seizure, Yi, was the Lomax distribution. We
therefore consider these survival distributions for the two post-randomisation
survival times separately, namely time to rst seizure and time from rst to
second seizure. The Log-logistic and Lomax distributions are dened by the
following probability density functions:
 Log-logistic (shape=, scale=1=i)
fY (yi;i; ) =
i(iyi)
 1
(1 + (iyi))2
; (4.2)
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 Lomax (shape=, scale==i)
fY (yi;i; ) = i
 
 + iyi
+1
; (4.3)
where in each model i = exp(
0di) for a vector  of regression coecients,
and a vector di of covariates for each individual i, including an intercept term.
Increasing values of the m regression coecients, k, k = 0; : : : ;m, correspond
to an increase in the acceleration factor, and hence a decrease in the expected
time to seizure. Conversely, negative values of k, k = 0; : : : ;m, correspond to
deceleration and an increase in the expected time to seizure. The parameter
 > 0 is a shape parameter and represents the degree of additional hetero-
geneity within the population, with smaller values indicating higher levels of
heterogeneity.
Recall that exploratory analysis supported the use of the Log-logistic distribu-
tion and note that equations (4.2) and (4.3) are equivalent when  = 1. Hence
a value of  close to 1 (indicating that there is considerable heterogeneity in
the population) would suggest that the data could be suciently modelled
through the Lomax distribution, validating the use of the joint model pro-
posed by Cowling et al. (2006) and presented in Chapter 2. We now present
the estimated regression coecients obtained when each of these distributions
is t to the post-randomisation survival times, time to rst seizure and time
from rst to second seizure.
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Time to First Seizure
The parameter estimates for time to rst seizure only, for the Log-Logistic
and Lomax distributions are given in Table 4.2. The reference group contains
individuals with partial seizures pre-randomisation, with a normal EEG and
randomised to deferred treatment.
Regression Estimates (standard errors) for
Coecient the following models:
Log-logistic Lomax
0 -0.381 (1.156) 0.572 (1.016)
trt -1.217 (1.421) -0.927 (1.319)
t c -0.567 (0.604) -0.494 (0.602)
2t c -0.853 (0.620) -0.660 (0.624)
partial reference reference
eeg -0.340 (1.399) 0.072 (1.283)
ln(rate) 1.227 (0.217) 1.138 (0.189)
t ctrt -0.968 (0.648) -1.040 (0.663)
2t ctrt -0.976 (0.665) -0.898 (0.684)
partialtrt reference reference
eegtrt -1.118 (0.347) -1.138 (0.357)
ln(rate)trt -0.366 (0.266) -0.327 (0.251)
t ceeg 0.598 (0.666) -0.032 (0.246)
2t ceeg 1.668 (0.685) 0.497 (0.685)
partialeeg reference reference
ln(rate)eeg -0.117 (0.264) 1.190 (0.708)
 0.617 (0.021) 0.233 (0.008)
-Log-likelihood (d.f.) 5112 (1321) 5096 (1321)
Table 4.2: Estimated regression coecients, for the two survival models, tted
to the times to rst seizure.
We begin by conducting the Wald test (Wald 1943) on each of the estimated
regression coecients given in Table 4.2 and nd that for both survival dis-
tributions the only statistically signicant covariates are ln(rate) and eegtrt.
Furthermore, those experiencing tonic-clonic only and secondary tonic-clonic
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seizures pre-randomisation can typically expect to have a longer time to rst
seizure post-randomisation, than those with partial seizures only. Additionally
2t ceeg is signicant in the Log-logistic model only. The lack of statistically
signicant covariates in these models is contrary to the observations made
through the investigation of the Kaplan-Meier curves. Probably most surpris-
ing is that the exploratory analysis suggested that treatment policy should be
signicant, but this is not supported by the coecient estimates.
The Log-logistic and Lomax distributions can not be compared using the
standard likelihood ratio test, as they are non-nested models. The Akaike
Information Criterion (AIC) (Sahamotoa et al. 1986) is a method for compar-
ing two non-nested models and is given by 2(m  `), where m is the number of
parameters in the model and ` is the maximised log-likelihood associated with
the model. Computing the AIC for each of the two survival distributions we
have that for time to rst seizure the AIC for the Log-logistic model is 10250,
and for the Lomax distribution the corresponding AIC is 10217. This indicates
that the Lomax distribution is preferred over the Log-logistic distribution.
Time from First to Second Seizure
The parameter estimates for the times from rst to second seizure, for the
Log-Logistic and Lomax distributions are given in Table 4.3. If we compute
the AIC for each of these distributions we have that for the Log-logistic dis-
tribution the AIC is 5652, and the AIC for the Lomax distribution is 5614,
meaning that again the Lomax distribution is the preferred of the two distri-
butions.
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If we now compute the Wald statistics for each of the estimated regression coef-
cients presented in Table 4.3, we see that only t c is statistically signicant
in the Lomax survival distribution. Additionally, only ln(rate) is signicant
in the Log-logistic distribution. This time, however, the lack of statistically
signicant covariates is not as surprising. The exploratory analysis suggested
that some covariates that were statistically signicant in determining the times
to rst seizure failed to be statistically signicant when considering the times
from rst to second seizure.
Regression Estimates (standard errors) for
Coecient the following models:
Log-logistic Lomax
0 -0.234 (1.497) -0.085 (1.294)
trt -2.183 (1.893) -1.650 (1.708)
t c -1.770 (0.894) -2.188 (0.783)
2t c -0.364 (0.901) -1.063 (0.802)
partial reference reference
eeg -2.013 (1.800) -0.918 (1.616)
ln(rate) 0.780 (0.294) 0.440 (0.250)
t ctrt 1.747 (0.932) 1.121 (0.874)
2t ctrt 0.647 (0.944) 0.540 (0.887)
partialtrt reference reference
eegtrt 0.492 (0.499) 0.382 (0.481)
ln(rate)trt -0.175 (0.369) -0.148 (0.342)
t ceeg 0.192 (0.953) 0.920 (0.902)
2t ceeg 0.043 (0.966) 0.716 (0.917)
partialeeg reference reference
ln(rate)eeg -0.301 (0.354) 0.040 (0.325)
 0.595 (0.024) 0.270 (0.012)
-Log-likelihood (d.f.) 2813 (1321) 2794 (1321)
Table 4.3: Estimated regression coecients, for the two survival models, tted
to the times from rst to second seizure.
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4.3 Discussion
In Chapter 3, exploratory analysis was carried out on 1425 individuals. In the
formal analysis of the MESS data however, ve individuals, for whom there
was no information on their pre-randomisation seizure history, were removed,
as were all those individuals presenting with either generalised or other seizures
pre-randomisation. This left us with a nal sample size of 1334 individuals all
presenting with tonic-clonic and/or partial seizures.
The Negative Binomial Generalised Linear Model was considered as a marginal
model for the event counts, with the Log-logistic and Lomax accelerated fail-
ure time models being adopted for the marginal survival times.
Seizure type was found to be statistically signicant in determining an individ-
uals' pre-randomisation seizure count. Those individuals experiencing partial
seizures only, typically have more seizures pre-randomisation, than those pre-
senting with tonic-clonic seizures.
In the analysis of the post-randomisation survival times, the Lomax distri-
bution was found to be more suitable than the Log-logistic distribution for
both times to rst, and from rst to second seizures. A lack of statistically
signicant exploratory variables was observed. This surprising result is in stark
contrast to the conclusions drawn following the examination of the Kaplan-
Meier curves in Chapter 3.
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Chapter 5
The Joint Model
Analysis of the post-randomisation survival times in a univariate setting, using
standard survival distributions, was unable to pick up on covariate eects that
were suggested by the examination of the Kaplan-Meier curves.
Cowling et al. (2006) compared the joint model for pre-randomisation event
counts and post-randomisation survival times with the best tting standard
survival distribution that treated the pre-randomisation event count informa-
tion as a covariate. A simulation study of power (Cowling 2003) indicated
that the joint model provided more precise estimates of the treatment eect
than the standard parametric survival models. The joint model also had more
power to identify interaction eects not armed by the standard survival mod-
els.
We shall use the model developed by Cowling et al. (2006) as the basis for
a joint model that analyses pre-randomisation event counts and two post-
randomisation survival times together.
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5.1 Building the Joint Model for the Event
Counts Pre-Randomisation and Two Post-
Randomisation Survival Times
In many treatment studies it is often time to rst event that is measured,
however epilepsy is characterised by recurrent seizures, not a single, isolated
event. Our data arrives in three parts: a pre-randomisation event count, post-
randomisation time to rst seizure and post-randomisation time from rst to
second seizure. Our aim is to develop methodology that analyses these out-
comes jointly, in a single model.
Let T1i and T2i be the times from randomisation to rst and second seizure
respectively, for individual i, i = 1 : : : n. Now, setting Y1i = T1i and Y2i =
T2i  T1i, gives that Y1i is subsequently the time to rst seizure, and Y2i is the
time from rst seizure to the second. We shall assume individuals experience
seizures according to a Poisson process with rate ii, where the parame-
ter i relates to the baseline covariates, with additional heterogeneity in the
population being modelled through i, assumed to follow a Gamma(; ) dis-
tribution. Smaller values of  are indicative of higher levels of heterogeneity.
Consequently, the pre-randomisation event count, for individual i, over period
ui, Xi, follows a Poisson distribution with mean and variance iuii.
A consequence of the Poisson process is that interevent times are Exponential,
so that post-randomisation survival times to rst seizure, and from rst to
second seizure, Y1i and Y2i, will be independent, conditional on the random
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eect term, and Exponentially distributed with rate i ii. The parameter
 i is a post-randomisation seizure rate modier, related to the individuals'
treatment in some way. In summary:
Xi j i  Poisson(iuii);
Yji j i  Exponential(i ii); j = 1; 2;
i  Gamma(; ):
The joint density of the survival times is the product of the densities of Y1i
and Y2i, so that the joint model is specied by the following equations:
fXj(xi j i;i; ui) = (iuii)
xi exp( iuii)
xi!
;
fY1;Y2j(y1i; y2i j i;i;  i) = (i ii)2 exp( i ii(y1i + y2i));
f(i;) =
 1i exp( i)
 ()
;
where i = exp(
0
1z1i),  i = exp(
0
2z2i) and z1i, z2i are vectors of covariates,
not necessarily distinct.
5.1.1 Marginal Distributions
If the random eect term is integrated out of the joint density of Xi and i,
then the resulting unconditional density, fX(xi;i; ui; ), is simply the Nega-
tive Binomial (Equation 4.1). The unconditional joint distribution of the Yji,
j = 1; 2, obtained when the random eects are integrated out of the joint
density of the survival times, Y1i and Y2i, and i, is the bivariate Lomax distri-
bution (Nayak 1987). This distribution has the following density and survivor
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functions:
fY1;Y2(y1i; y2i;i;  i; ) =
Z 1
0
fY1;Y2j(y1i; y2i j i;i;  i)g(i;)di
=
+ 1

(i i)
2

1 +
i i(y1i + y2i)

 (+2)
(5.1)
SY1;Y2(y1i; y2i;i;  i; ) =
Z 1
y2i
Z 1
y1i
fY1;Y2(u; v;i;  i; )du dv
=

1 +
i i(y1i + y2i)

 
: (5.2)
Each of the Yji have univariate Lomax marginal distributions, with shape and
scale parameters  and =i i respectively, with density:
fYj(yji;i;  i; ) =
i i
(1 + i iyji=)+1
; j = 1; 2:
5.1.2 The Full Log-Likelihood and Derivatives
When formulating the likelihood, we need to consider the dierent ways that
censoring can occur. There are three dierent ways censoring can arise in this
setting, namely: (i) Y1i and Y2i are both observed, (ii) Y1i is observed, but Y2i
is censored, and (iii) Y1i is censored, so Y2i is taken to be censored at zero. We
now consider these three situations separately.
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Joint Distribution with Y1i and Y2i Observed
In this situation the joint density of Y1i and Y2i contributes towards the like-
lihood, giving
Z 1
0
fXj(xi j i;i; ui)fY1;Y2j(y1i; y2i j i;i;  i)f(i;)di
=
(iui)
xi
xi!
(i i)
2
 ()
 (xi + + 2)
(iui + i i(y1i + y2i) + )xi++2
: (5.3)
Joint Distribution with Y1i Observed and Y2i Censored
In this situation the density of Y1i and the survivor function for Y2i contribute
to the likelihood, giving
Z 1
0
fXj(xi j i;i; ui)fY1j(y1i j i;i;  i)SY2j(y2i j i;i;  i)f(i;)di
=
(iui)
xi
xi!
i i

 ()
 (xi + + 1)
(iui + i i(y1i + y2i) + )xi++1
: (5.4)
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Joint Distribution with Y1i Censored, so Y2i Taken to be Censored
at Zero
In this situation it is the survivor functions of Y1i and Y2i that will contribute
to the likelihood, however we assume that the second survival time is censored
at zero, giving SY2j(0 j i;i;  i) = 1.
Z 1
0
fXj(xi j i;i; ui)SY1j(y1i j i;i;  i)f(i;)di
=
(iui)
xi
xi!

 ()
 (xi + )
(iui + i iy1i + )xi+
: (5.5)
Conversely, by keeping SY2j(y2i j i;i;  i) in the calculations, we subsequently
obtain a simpler likelihood function, so we proceed in this way to obtain
Z 1
0
fXj(xi j i;i; ui)SY1j(y1i j i;i;  i)SY2j(y2i j i;i;  i)f(i;)di
=
(iui)
xi
xi!

 ()
 (xi + )
(iui + i i(y1i + y2i) + )xi+
: (5.6)
Note that equations (5.5) and (5.6) are equivalent when y2i = 0.
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Log-likelihood
Let ji be the indicator function for the jth survival time, taking the value 1
if the seizure is observed, and zero if the survival time is censored. Combining
these indicator functions with equations (5.3)-(5.6) allows us to formulate the
log-likelihood for the observed data D, for all the n individuals, given by
`(;1;2 j D) =
nX
i=1
 xi 1X
k=0
ln(+ k)

+ (xi + 1i(1 + 2i)) ln(i) + xi ln(ui)
  ln(xi!) +  ln() + 1i(1 + 2i) ln( i) + 1i ln(xi + )
+1i2i ln(xi + + 1)  (1  1i)(xi + ) ln (iui + i iy1i + )
 1i(2i + xi + + 1) ln (iui + i i(y1i + y2i) + )

: (5.7)
First and second derivatives of this log-likelihood can easily be obtained, al-
lowing inference on the parameters , 1 and 2 using a numerical method
such as Newton Raphson.
First Derivatives
The rst-order derivatives of the full log-likelihood are
@`
@1
=
nX
i=1

(xi + 1i(1 + 2i)  iui   i i(y1i + y2i))
iui + i i(y1i + y2i) + 

z1i;
@`
@2
=
nX
i=1

1i(1 + 2i)(iui + )  i i(y1i + y2i)(xi + )
iui + i i(y1i + y2i) + 

z1i;
@`
@
=
nX
i=1
 xi 1X
k=0
1
+ k

+
1i
xi + 
+
1i2i
xi + + 1
+ ln() + 1
  ln(iui + i i(y1i + y2i) + )  xi + + 1i(1 + 2i)
iui + i i(y1i + y2i) + 

:
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Second Derivatives
The second-order derivatives of the full log-likelihood are
@2`
@1@10 =  
nX
i=1

(xi + 1i(1 + 2i + )(iui + i i(y1i + y2i))
(iui + i i(y1i + y2i) + )
2

z1iz1i0;
@2`
@1@20 =  
nX
i=1

(+ xi + 1i(1 + 2i))i i(y1i + y2i)
(iui + i i(y1i + y2i) + )
2

z1iz2i0;
@2`
@1@
=
nX
i=1

(iui + i i(y1i + y2i))(xi + 1i(1 + 2i)  iui
(iui + i i(y1i + y2i) + )
2
  i i(y1i + y2i))
(iui + i i(y1i + y2i) + )
2

z1i;
@2`
@2@20 =  
nX
i=1

(xi + + 1i(1 + 2i))(iui + )i i(y1i + y2i)
(iui + i i(y1i + y2i) + )
2

z2iz2i0;
@2`
@2@
=
nX
i=1

(xi   iui + 1i(1 + 2i))i i(y1i + y2i)
(iui + i i(y1i + y2i) + )
2
 (i i(y1i + y2i))i i(y1i + y2i)
(iui + i i(y1i + y2i) + )
2

z2i;
@2`
@@
=  
nX
i=1
 xi 1X
k=0
1
(+ k)2

+
1i
(xi + )2
+
1i2i
(xi + + 1)2
  1

 (xi + 1i(1 + 2i)    2(iui + i i(y1i + y2i)))
(iui + i i(y1i + y2i) + )
2

:
5.2 Implementing the Joint Model
We consider two versions of the joint model: the joint model proposed by
Cowling et al. (2006), which considers the pre-randomisation event counts and
times to rst post-randomisation seizure only (Joint Model A), and the joint
model we have developed here that models the pre-randomisation event counts
and post-randomisation seizure times to rst and second seizure (Joint Model
B). The estimated regression coecients for the two tted models are given
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in Table 5.1. A regression coecient > 0 (< 0) would indicate an increased
(decreased) seizure rate relative to the seizure rate in the reference group. The
reference group contains individuals with partial seizures pre-randomisation,
with a normal EEG and randomised to deferred treatment.
It is encouraging to note that the estimated regression coecients contained in
i are very similar to those obtained through the Negative-Binomial marginal
count model, presented in Table 4.1.
If we conduct the Wald test on each of the regression coecients in  i we
can see that in the joint models there are numerous signicant covariates,
indeed all but the pre-randomisation seizure types and EEG outcome are sig-
nicant. It may be surprising to conclude that the pre-randomisation seizure
types are not signicant in the model, but note that the interaction terms are
highly signicant.
If we compare the signicant variables appearing in  i, for each of the two mod-
els considered, the estimated regression coecients observed in Joint Model
B are closer to zero than those estimates observed in Joint Model A. Recall
that the exploratory analysis suggested that covariates that were signicant in
determining the times to rst seizure post-randomisation, may not be signi-
cant when analysing the times from rst to second post-randomisation seizure.
This may explain the averaging down eect observed here and suggests that we
should not assume that the  i remains constant between post-randomisation
seizures.
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Regression Estimates (standard errors)
Coecient for the following models:
Joint Model A Joint Model B
 1.942 (0.105) 1.738 (0.092)
i 1;0 -4.133 (0.087) -4.145 (0.091)
1;t c -1.074 (0.097) -1.054 (0.100)
1;2t c -0.694 (0.100) -0.697 (0.103)
1;partial reference reference
 i 2;0 -2.759 (0.327) -2.067 (0.252)
2;trt 0.979 (0.331) 0.433 (0.263)
2;t c 0.549 (0.337) 0.057 (0.262)
2;2t c 0.242 (0.347) 0.067 (0.270)
2;partial reference reference
2;eeg -0.251 (0.338) -0.537 (0.268)
2;t ctrt -1.214 (0.333) -0.491 (0.265)
2;2t ctrt -1.340 (0.346) -0.854 (0.274)
2;partialtrt reference reference
2;eegtrt -0.629 (0.184) -0.377 (0.148)
2;t ceeg 0.777 (0.347) 0.875 (0.277)
2;2t ceeg 1.478 (0.359) 1.272 (0.286)
2;partialeeg reference reference
-Log-likelihood (d.f.) 7872 (1320) 11233 (1320)
Table 5.1: Estimated regression coecients for the joint models. The term i
contains parameter estimates corresponding to the eect of covariates on the
underlying event rate and  i contains parameter estimates corresponding to
the eect of covariates on the post-randomisation reduction in event rates.
5.3 Interpretation of Results
To gain a better understanding of the estimated regression coecients, given
in Table 5.1, we can obtain subsequent estimates of the pre-randomisation
seizure rates and the post-randomisation seizure rate modiers, for the dif-
ferent seizure types, EEG outcomes and treatment policies. We shall use the
estimates given by Joint Model B.
Table 5.2 gives the expected pre-randomisation seizure rates per unit time,
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for the dierent seizure types. We can see that those individuals presenting
with partial seizures pre-randomisation can typically expect to have the highest
seizure rate, with those experiencing tonic-clonic seizures only and secondary
tonic-clonic seizures having statistically signicantly lower rates.
Seizure Type bi (95% C.I.) Expected
yearly rate
Tonic-Clonic 0.0055 (0.005,0.006) 2
2 Tonic-Clonic 0.008 (0.007,0.009) 3
Partial 0.016 (0.013,0.019) 6
Table 5.2: The expected pre-randomisation seizure rate per unit time and
the corresponding expected yearly seizure rate, using the estimated regression
coecients from Joint Model B.
Table 5.3 gives estimates of the expected post-randomisation change in seizure
rate, stratied by seizure type, EEG outcome and treatment policy. As
an example consider a person presenting with tonic-clonic seizures only pre-
randomisation, with an abnormal EEG and randomised to deferred treat-
ment. Table 5.2 tells us that their expected pre-randomisation seizure rate
per unit time, bi, is 0:0055, which equates to a seizure approximately ev-
ery 182 days. Their subsequent b i, from Table 5.3, is 0:188, meaning that
post-randomisation they should expect to have seizures about 19% as often as
they had experienced pre-randomisation. Recall that the post-randomisation
seizure rate per unit time is given by bi b i = 0:0055  0:188 = 0:0010, which
equates to one seizure approximately every 970 days.
Looking at the values of b i presented in Table 5.3, we can see that treat-
ment policy is not statistically signicant for those individuals with a normal
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EEG. Additionally, those individuals having an abnormal EEG, but allocated
to immediate treatment, can expect to have a post-randomisation seizure rate
in line with those presenting a normal EEG. We can see that for those with an
abnormal EEG, immediate treatment is favoured for all groups except partial,
where no signicant dierence between treatment policies is observed. This is
in line with what was suggested by the exploratory analysis.
Seizure Type b i (95% C.I.)
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.122 (0.10,0.15) 0.188 (0.15,0.23)
2 Tonic-Clonic 0.127 (0.10,0.16) 0.282 (0.22,0.36)
Partial 0.078 (0.05,0.12) 0.074 (0.05,0.11)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.127 (0.10,0.15) 0.134 (0.11,0.16)
2 Tonic-Clonic 0.089 (0.07,0.11) 0.135 (0.11,0.17)
Partial 0.195 (0.12,0.32) 0.127 (0.08,0.21)
Table 5.3: The expected change in seizure rate post-randomisation, using the
estimated regression coecients from Joint Model B.
If we further consider the values of the expected post-randomisation seizure
rate reductions, presented in Table 5.3, we observe large reductions in the
seizure rates across all groups. Note that the estimates presented suggest
that even those individuals with an abnormal EEG and randomised to de-
ferred treatment should expect to see considerable reductions in their seizure
rate post-randomisation. It seems unrealistic that an individual receiving no
treatment should expect to see such dramatic reductions in their seizure rate
post-randomisation.
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5.4 Discussion
In this chapter we have built a model that allows pre-randomisation event
counts and post-randomisation times to rst, and from rst to second seizure,
to be analysed jointly. This model is proposed as an alternative to standard
survival analysis, which treats the pre-randomisation event count information
as a covariate, and was based on a joint model developed by Cowling et al.
(2006). We have built our joint model under a Poisson process framework,
with an assumed underlying individual event rate. This underlying seizure
rate is modied at randomisation to allow for the treatment eects. We have
assumed that post-randomisation survival times are independent, conditional
on the individual-specic random eects, and identically distributed.
The joint model that has been developed in this chapter has subsequently
been used to analyse the MESS data. Two versions of the joint model were
considered: one that jointly analyses the pre-randomisation event count and
time to rst seizure post-randomisation only (Joint Model A), and a second
that additionally incorporates the times from rst to second seizure (Joint
Model B). On tting the joint models, we concluded that the seizure type
interactions with treatment and EEG outcome were highly statistically signif-
icant.
To gain a better understanding of the regression coecients presented, subse-
quent estimates of the pre-randomisation seizure rates and post-randomisation
seizure rate modiers were derived. These estimates revealed possible limita-
tions of the joint model presented in this chapter. First, the magnitudes of
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the seizure rate reductions presented in Table 5.3 are a cause for concern.
Non-parametric analysis of the data, carried out in Chapter 3, highlighted the
possibility of cure rates being prevalent in the dataset, which would explain
the unrealistic reductions in seizures rates observed here.
Secondly, we have noted that the estimated regression coecients observed
in Joint Model B are closer to zero than those estimates observed in Joint
Model A. This result has suggested that the assumption of a constant  i post-
randomisation may be violated.
The joint models for the pre-randomisation and post-randomisation seizure
rates, developed in this chapter, seem to provide an improvement over stan-
dard survival models. The inclusion of additional information in the joint
models has resulted in an increase in power, which consequently means that
statistically signicant covariate eects, not recognised by the standard sur-
vival distributions, have been armed.
Previously analyses of the MESS data, by Marson et al. (2005) and Kim
et al. (2006), concluded that the risk of seizure recurrence increased with the
number of seizures pre-randomisation and an abnormal EEG, and that imme-
diate treatment increased times to rst and second seizures. These ndings are
consistent with our analysis of the MESS data. Nonetheless, neither of these
analyses considered dierences between types of epileptic seizures, or interac-
tions between the covariates, which we have found to be statistically signicant
in determining underlying seizure rates and post-randomisation seizure rate re-
ductions.
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To summarise, despite an observed improvement, the joint model does not
incorporate other characteristics evident within the data, and discussed here.
Extensions to the joint model that accommodate these interesting character-
istics in the dataset shall be considered in the next chapter.
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Chapter 6
Extensions to the Simple Joint
Model
As previously discussed, examination of the results obtained following the im-
plementation of Joint Models A and B, has highlighted possible limitations.
The assumption of a constant seizure rate post-randomisation may not be ac-
curate, and there is evidence to suggest that cure rates may be present.
In this next section we discuss each of these limitations separately and ex-
plore possible solutions to the problems that they present. We shall then
proceed to build a model that encompasses all the interesting characteristics
present in the data, in one complete model.
6.1 Varying Post-Randomisation Seizure Rate
There is evidence to suggest that the seizure rates may change not only at
randomisation, but also following a rst seizure post-randomisation. We shall
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account for this by rst considering the following adjustment:
Xi j i  Poisson(iuii);
Y1i j i  Exponential(i 1ii);
Y2i j i  Exponential(i 1ii);
i  Gamma(; );
where i = exp(
0
1z1i),  1i = exp(
0
2z2i) and z1i, z2i are vectors of covariates,
not necessarily distinct. The parameter  is a constant, which determines the
change in seizure rate following a post-randomisation seizure.
Integrating the random eect term out of the joint density of the survival times,
Y1i and Y2i, and i, the unconditional joint distribution of the Yji, j = 1; 2,
remains the bivariate Lomax distribution, with univariate Lomax marginal
distributions. Proceeding in the same manner as before, considering the dif-
ferent censoring patterns separately, allows us to formulate the log-likelihood
for the observed data D, on all the n individuals, obtaining
`(;1;2;  j D) =
nX
i=1
 xi 1X
k=0
ln(+ k)

+ fxi + 1i(1 + 2i)g ln(i)
+xi ln(ui)  ln(xi!) +  ln() + 1i(1 + 2i) ln( 1i) + 1i2i ln()
+1i ln(xi + ) + 1i2i ln(xi + + 1) (6.1)
 fxi + + 1i(1 + 2i)g ln (iui + i 1i( y1i + y2i) + )

:
The derivation of this adjusted model allows us to conduct a hypothesis test,
comparing Joint Model B with the model that we consider here. The estimate
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for  was 2.2 (standard error 0.16)1, with the corresponding log-likelihood ratio
test statistic of 2468 providing overwhelming support for its inclusion.
We do not believe that this model is sucient for modelling the data, we merely
use this example to illustrate that the identically distributed assumption for
the two survival times is violated. Instead, we now consider a joint model that
includes seizure rate modiers, both at randomisation and following a rst
post-randomisation seizure, that depend on covariates. This modication is
implemented by considering the following adjustment to the joint density for
the post-randomisation survival times:
fY1;Y2j(y1i; y2i j i;i;  1i;  2i) = (i 1ii)2 2i exp( i 1ii(y1i +  2iy2i));
where i = exp(
0
1z1i),  1i = exp(
0
2z2i),  2i = exp(
0
3z3i) and z1i, z2i, z3i
are vectors of covariates, not necessarily distinct.
Table 6.1 shows the subsequent estimated pre-randomisation seizure rates and
the expected yearly seizure rates, stratied by seizure type. It is not sur-
prising to observe that the gures presented in Table 6.1 are the same as
those presented in Table 5.2. The extensions that we consider in this chap-
ter correspond to interesting characteristics present in the post-randomisation
survival times only. There is no reason why, by considering extensions to the
simple joint model, we should expect parameter estimates concerning the pre-
randomisation event counts to change.
1Maximum likelihood estimates of the regression coecients for
the dierent models considered in this chapter can be found at
http://www.warwick.ac.uk/go/jenniferrogers/research/thesis.
This page is password protected, the password is `thesisrogers2010'.
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Seizure Type bi (95% C.I.) Expected
yearly rate
Tonic-Clonic 0.0054 (0.005,0.006) 2
2 Tonic-Clonic 0.008 (0.007,0.009) 3
Partial 0.016 (0.013,0.019) 6
Table 6.1: The expected pre-randomisation seizure rate per unit time and
the corresponding expected yearly seizure rate, using the estimated regression
coecients from Joint Model B.
Table 6.2 shows the maximum likelihood estimates for  1i and  2i. The values
of  1i represent the change in seizure rate at randomisation, with  2i repre-
senting the change in rate following a rst post-randomisation seizure. As in
Chapter 5, we see that treatment policy does not appear to be statistically sig-
nicant in determining the estimate of  1i for those individuals with a normal
EEG. Additionally, those individuals having an abnormal EEG, but allocated
to immediate treatment can expect to have a seizure rate following randomisa-
tion in line with those presenting a normal EEG. For those with an abnormal
EEG immediate treatment is favoured for all groups except partial, where no
statistically signicant dierence between treatment policies is observed.
Following a rst seizure post-randomisation we see that, in general, seizure
rates increase. Those with an abnormal EEG, and allocated to deferred treat-
ment, typically have the smallest increase in seizure rate following a rst seizure
post-randomisation. A possible explanation for this is that these individuals
typically see the smallest reduction in seizure rate following randomisation.
Recall that those randomised to deferred treatment were simply withheld
AEDs until it was deemed absolutely necessary by the clinician. It seems
reasonable to suggest that those individuals who were randomised to deferred
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treatment, who experience a seizure post-randomisation, may start a subse-
quent course of treatment with AEDs, thus bringing them in line with those
randomised to immediate treatment.
Seizure Type b 1i (95% C.I.) rst seizure
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.086 (0.07,0.11) 0.157 (0.12,0.20)
2 Tonic-Clonic 0.109 (0.08,0.14) 0.227 (0.17,0.31)
Partial 0.052 (0.03,0.09) 0.065 (0.04,0.10)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.094 (0.08,0.12) 0.107 (0.09,0.13)
2 Tonic-Clonic 0.067 (0.05,0.09) 0.087 (0.07,0.11)
Partial 0.119 (0.06,0.22) 0.093 (0.05,0.17)b 2i (95% C.I.) second seizure
Abnormal EEG
Immediate Deferred
Tonic-Clonic 3.755 (2.48,5.70) 1.413 (0.99,2.01)
2 Tonic-Clonic 1.708 (1.12,2.62) 1.361 (0.89,2.08)
Partial 2.202 (0.99,4.91) 2.134 (1.01,4.53)
Normal EEG
Immediate Deferred
Tonic-Clonic 3.116 (2.19,4.43) 1.983 (1.41,2.78)
2 Tonic-Clonic 3.640 (2.31,5.73) 4.902 (3.18,7.56)
Partial 1.814 (0.74,4.46) 2.972 (1.19,7.44)
Table 6.2: The expected change in seizure rates following randomisation
and following the rst post-randomisation seizure, using the estimated re-
gression coecients from the joint model that incorporates a varying post-
randomisation seizure rate.
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6.2 Cure Rate Models
The magnitude of the reductions in seizure rates post-randomisation, observed
in Chapter 5 suggest that there may be a substantial proportion of the pop-
ulation that we should regard as cured. This was also discussed in the ex-
ploratory analysis, presented in Chapter 3. Berg and Shinnar (1991) noted
that, on average, around 50% of people do not experience seizure recurrence
after a single, untreated seizure. Recall that over half of the 1425 individuals
for whom exploratory analysis was carried out presented only a single seizure
pre-randomisation. It is therefore not unreasonable to suspect that a substan-
tial proportion of the individuals included in the MESS trial would never have
a seizure post-randomisation, regardless of the length of time for which they
were followed. It has already been acknowledged that if survival data does in-
deed have a proportion that are immune to the event of interest, a model that
ignores this may give misleading results. More specically, ignoring any po-
tential cure fraction could result in underestimates of the post-randomisation
seizure rates, thus contributing to the magnitude of seizure rate reductions
that have been observed.
Recall that a proper survival distribution should have total mass 1, with the
resulting Kaplan-Meier curve having its asymptote at zero. The Kaplan-Meier
curves for times to rst seizure, and from rst to second seizure, are presented
in Figure 6.1. Both of the Kaplan-Meier curves level o well above zero, sug-
gesting that there may be an immune component present for both time to rst
seizure post-randomisation and time from rst to second seizure.
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Figure 6.1: Kaplan-Meier curves for time to rst and second seizures (with
95% CI). Curves are marked at each censoring time.
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We have presented a cure rate model, proposed by Maller and Zhou (1996),
which takes into consideration the fact that there may be a proportion of
individuals in the population immune to the event of interest. We shall now
proceed to consider the analysis of the MESS data using cure rate models.
6.2.1 Standard Survival Analysis with Cure Rates
Standard software in R (Peng ) allows the tting of various parametric mix-
ture models, including the Log-logistic, for the estimation of cure rates. We
therefore proceed to t a Log-logistic mixture model that incorporates a cure
fraction. This model was considered for both times to rst seizure post-
randomisation, and times from rst to second seizure.
We initially consider mixture models that allow the associated cure rates to
depend on an intercept term only. The derivation of these adjusted models
allows us to conduct a hypothesis test, comparing the Log-logistic cure rate
models with the standard Log-logistic models presented in Chapter 4. The
estimated cure fractions are 23.9% for time to rst seizure, and 19.3% for
time from rst to second seizure. The corresponding log-likelihood ratio test
statistics are 6236 and 3268 for the models for time to rst seizure and time
from rst to second seizure respectively. These two highly statistically signif-
icant test statistics provide overwhelming evidence for the inclusion of cure
rates, when analysing the survival data. These estimated values, however, are
slightly lower than suggested by the Kaplan-Meier curves in Figure 6.1, but
still provide sucient evidence to suggest that we should incorporate a cure
fraction into the joint model.
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Further investigation concluded that the cure rates associated with times to
rst seizure post-randomisation are dependent on seizure type, EEG outcome
and the logarithm of the pre-randomisation seizure rate for each individual.
For the times from rst to second post-randomisation, no covariate eects were
found to be statistically signicant in determining the proportion cured.
6.2.2 Cure Rate for Single Post-Randomisation Survival
Time
We can adjust our original, simple joint model, to allow for the inclusion of
cure rates. We rst consider a model that jointly models the pre-randomisation
seizure counts and post-randomisation time to rst seizure only, which has the
following density and survivor functions:
fY1j(y1i j i;i;  i; p) = pgY1j(y1i j i;i;  i)
= pi ii exp( i iiy1i);
SY1j(y1i j i;i;  i; p) = 1  p+ pRY1j(y1i j i;i;  i)
= 1  p+ p exp( i iiy1i);
where i = exp(
0
1z1i),  i = exp(
0
2z2i) and z1i, z2i are vectors of covariates,
not necessarily distinct. The term p represents the susceptible proportion in
the population, so that 1   p is the cure fraction. The density and survivor
functions for the susceptibles are given by g() and R() respectively.
On tting the joint model allowing for the cure rate, we obtain a maximum
likelihood estimate for p of 0.574 (standard error 0.02). Comparing this esti-
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mate with the Kaplan-Meier curve for time to rst seizure in Figure 6.1, this
estimate seems sensible. We can formally test for the inclusion of p by compar-
ing the log-likelihood of Joint Model A with the log-likelihood obtained here.
A highly statistically signicant likelihood-ratio test statistic of 442 supports
the inclusion of the cure rate, and the corresponding estimated value suggests
that there is a substantial proportion of the population `immune' to seizures
post-randomisation.
6.2.3 Allowing the Cure Rates to Depend on Covariates
We can allow the cure rate to depend on individuals' covariates by considering
the following parameterisation:
pi =
exp(0wi)
1 + exp(0wi)
:
The explanatory variables associated with individual i are entered into the
covariate wi, with  denoting the corresponding vector of regression coe-
cients. Estimates of bi will remain the same as those presented in Tables 5.2
and 6.1. Subsequent parameter estimates can be used to obtain estimates of
the post-randomisation seizure rate modiers and cure rates, denoted by b i
and 1  bpi respectively. Table 6.3 shows the estimated cure rates, whilst Table
6.4 presents the estimated seizure rate modiers for the subsequent susceptible
proportion. The results in Tables 6.3 and 6.4 allow us to estimate an individ-
uals' probability of being immune to seizure recurrence, dependent on their
pre-randomisation seizure types EEG outcome and their associated interac-
tion terms. If an individual is susceptible to seizure recurrence, we can predict
the magnitude of their seizure rate reductions post-randomisation, dependent
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on their pre-randomisation seizure types, EEG outcome and, additionally, the
treatment policy to which they are assigned.
Treatment policy was not found to be signicant in determining whether an
individual is susceptible or immune to seizure recurrence post-randomisation.
Model selection was carried out using stepwise backwards elimination (Hock-
ing 1976). Examination of Table 6.3 highlights that those individuals with
an abnormal EEG can expect to have a statistically signicantly lower cure
rate than those with a normal EEG, except for those individuals experiencing
Partial seizures only pre-randomisation, where no statistically signicant dif-
ference is observed.
Seizure Type 1  bpi (95% C.I.)
Abnormal EEG Normal EEG
Tonic-Clonic 0.352 (0.28,0.43) 0.495 (0.44,0.55)
2 Tonic-Clonic 0.235 (0.16,0.33) 0.549 (0.48,0.62)
Partial 0.391 (0.27,0.53) 0.280 (0.14,0.48)
Table 6.3: The expected cure rates when considering the times to rst seizure,
using estimates from the joint model that incorporates the post-randomisation
times to rst seizure only, with associated cure rates.
Looking at the estimated values of b i presented in Table 6.4, we can again see
that treatment policy does not appear to be signicant for those individuals
with a normal EEG. Those individuals having an abnormal EEG, but allocated
to immediate treatment, still expect to have a post-randomisation seizure rate
in line with those presenting a normal EEG. We can see that for those with
an abnormal EEG immediate treatment is favoured for all groups except par-
tial, where no signicant dierence between treatment policies is observed.
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Finally, we observe that the magnitudes of the seizure rate reductions post-
randomisation are not as large as those presented in Table 5.3. Additionally,
note that those with Partial seizures, with or without secondary Tonic-Clonic
seizures, with an abnormal EEG, and allocated to deferred treatment have
a value of b i not statistically signicantly dierent from unity, which corre-
sponds to the seizure rate not changing post-randomisation.
Seizure Type b i (95% C.I.)
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.189 (0.12,0.30) 0.638 (0.48,0.86)
2 Tonic-Clonic 0.186 (0.13,0.27) 0.761 (0.55,1.06)
Partial 0.431 (0.23,0.79) 0.683 (0.40,1.18)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.487 (0.36,0.66) 0.626 (0.47,0.84)
2 Tonic-Clonic 0.360 (0.23,0.55) 0.559 (0.40,0.79)
Partial 0.461 (0.23,0.92) 0.278 (0.13,0.59)
Table 6.4: The expected change in seizure rates following randomisation for the
susceptible proportion, using estimates from the joint model that incorporates
the post-randomisation times to rst seizure only, with associated cure rates.
6.2.4 Cure Rates for Both Post-Randomisation Survival
Times
We now develop a model that considers the pre-randomisation event counts
and both of the post-randomisation survival times, allowing each of the sur-
vival times to have an associated cure rate.
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In this scenario, censored times to rst seizure post-randomisation may be cen-
sored because individuals are immune to seizure recurrence or, alternatively,
their period of follow up may not be long enough to observe any seizures post-
randomisation, that is, the observation time may be less than their actual,
unobserved time to rst seizure.
These two distinct events have an eect on the subsequent post-randomisation
time from rst to second seizure. If an individual is immune to seizures post-
randomisation, then their time from rst to second seizure simply does not
exist. Alternatively, if the time to rst seizure exists but we do not observe
it, we know that an individual could either have a second post-randomisation
seizure (which we again do not observe), or they could, despite having a rst
seizure, be immune to further seizures.
We introduce, for each individual, an allocation variable, qi, which is an in-
dicator function taking the value 1 if the individual is susceptible to post-
randomisation seizure recurrence, and zero if the individual is immune.
Considering the dierent censoring patterns separately allows us to formulate
the log-likelihood for the observed data D, on all the n individuals, obtaining
92
`(;1;2;1;2 j D) =
nX
i=1
 xi 1X
k=0
ln(+ k)

+ xi ln(ui)  ln(xi!) +  ln()
+(xi + 1i(1 + 2i)) ln(i) + 1i(1 + 2i) ln( i) + 1i ln(p1i)
+1i2i ln(p2i) + 1i ln(xi + ) + 1i2i ln(xi + + 1)
 1i2i(xi + + 2) ln(iui + i i(y1i + y2i) + )
+(1  1i)qi ln

p1i
(iui + i iy1i + )xi+

+(1  1i)(1  qi) ln

1  p1i
(iui + )xi+

+1i(1  2i) ln

1  p2i
(iui + i iy1i + )xi++1
+
p2i
(iui + i i(y1i + y2i) + )xi++1

; (6.2)
where i = exp(
0
1z1i),  i = exp(
0
2z2i) and z1i, z2i are vectors of covariates,
not necessarily distinct. In addition,
p1i =
exp(01w1i)
1 + exp(01w1i)
;
p2i =
exp(02w2i)
1 + exp(02w2i)
:
In practice, we do not observe the allocation variable, qi, for each individual,
instead we can regard it as a missing value. We must now proceed to perform
likelihood inference in the presence of missing data. Little and Rubin (2002)
note that, in a formal sense, there is no dierence between maximum likelihood
for incomplete data and maximum likelihood for complete data: the likelihood
for the parameters, based on the incomplete data, is derived and the maximum
likelihood estimates are then found by solving the likelihood equation.
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Recall that the full model treats the missing data indicator as a random vari-
able, and considers the joint distribution of M and Y = (Yobs; Ymis). We have
already discussed how the full probability density function can be re-written
as the product of the probability density function of Y , and the conditional
distribution of M given Y . This conditional probability density function,
f(M j Yobs; Ymis;'), is indexed by the unknown parameter ', and is the distri-
bution of the missing-data mechanism. Recall that the actual observed data
are (Yobs;M), and the distribution of the observed data is obtained through
integrating Ymis out of the the joint density of Y and M (Equation 2.9). The
full likelihood of  and ' is then any function of  and ' proportional to the
joint probability distribution of Yobs and M :
Lfull(; ' j Yobs;M) / f(Yobs;M ; ; '); (; ') 2 
;': (6.3)
We can similarly let the likelihood of , based on Yobs, ignoring the missing-
data mechanism, be any function of  proportional to f(Yobs; ):
Lign( j Yobs) / f(Yobs; );  2 
: (6.4)
The subsequent question of importance is when inference for  should be based
on the full likelihood in Equation (6.3), and when it can be based on the sim-
pler, ignorable likelihood, given by Equation (6.4). The missing-data mech-
anism is ignorable for likelihood inference if the data are MCAR, or MAR,
and the parameters  and ' are distinct, in the sense that the joint parameter
space of (; ') is the product of the parameter space of  and the parameter
space of '.
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A common likelihood based technique, that is adopted when presented with
mixture models of the type presented in Equation 6.2, is the EM-algorithm.
The EM Algorithm
The EM algorithm is a general iterative algorithm for maximum likelihood
estimation, in the presence of missing data. This technique is based on a
somewhat ad-hoc idea of: (1) Replacing missing values by estimated values,
(2) Estimating parameters, (3) Re-estimating the missing values according to
the new parameter estimates, (4) Re-estimating the parameters, iterating until
convergence.
Suppose that the complete data are Y , with associated density f(Y ; ). We
write Y = (Yobs; Ymis), where Yobs represents the observed part of Y , and Ymis
denotes the missing part. The objective is to maximise the ignorable likeli-
hood,
Lign( j Yobs) =
Z
f(Yobs; Ymis; )dYmis;
with respect to .
The EM algorithm comprises an E-step and an M-step. The E-step nds the
conditional expectation of the `missing data', given the observed data and the
current estimated parameters. These expectations are then substitutes for the
`missing data'. We write `missing data' in quotation marks because, in real-
ity, the EM algorithm does not substitute the missing values themselves, but
regards the functions of Ymis appearing in the complete-data log-likelihood,
`( j Y ), as missing. The subsequent M-step simply comprises nding the
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maximum likelihood estimates of , as if there were no missing data. The
M-step uses exactly the same computational methods as maximum likelihood
estimation from `( j Y ).
The algorithm is formally dened as:
1. Choose initial value (0), set t=0.
2. E-step: calculate
Q(; (t)) = E[ln(L( j Yobs; Ymis))]
=
Z
`( j Y )f(Ymis j Yobs;  = (t))dYmis (6.5)
(at this stage (t) is xed and Q(; (t)) is a function of ).
3. M-step: nd (t+1) which maximises Q(; (t)) as a function of .
4. Set t = t+ 1 and go to step 2.
Essentially, each iteration of the EM algorithm updates (t) to (t+1) by solving
the following equation:
@
@
E[ln(L( j Yobs; Ymis))] = 0;
where (t) is used to nd E[ln(L( j Yobs; Ymis))], and (t+1) is the solution to
the equation. The main feature of the algorithm is that
L((t) j Yobs)  L((t+1) j Yobs):
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That is, the likelihood function is increased at each iteration of the algorithm
and consequently, the sequence, (0); (1); (2); : : :, is guaranteed to converge to
the location of a local maximum of the likelihood.
The complete-data log-likelihood is given by Equation (6.2). The parame-
ters to be maximised are  = f;1;2;1;2g. The observed data comprises
Yobs = fX; Y1; Y2; Z1; Z2;W1;W2; 1; 2g, and the missing data is Ymis = fQg.
To implement the EM-algorithm, using the iterative scheme outlined, we rst
carry out the E-step:
Q(; (t)) =
nX
i=1
 xi 1X
k=0
ln(+ k)

+ xi ln(ui)  ln(xi!) +  ln()
+(xi + 1i(1 + 2i)) ln(i) + 1i(1 + 2i) ln( i) + 1i ln(p1i)
+1i2i ln(p2i) + 1i ln(xi + ) + 1i2i ln(xi + + 1)
 1i2i(xi + + 2) ln(iui + i i(y1i + y2i) + )
+(1  1i)E(qi j Yobs; (t)) ln

p1i
(iui + i iy1i + )xi+

+(1  1i)(1  E(qi j Yobs; (t))) ln

1  p1i
(iui + )xi+

+1i(1  2i) ln

1  p2i
(iui + i iy1i + )xi++1
+
p2i
(iui + i i(y1i + y2i) + )xi++1

; (6.6)
where E(qi j Yobs; (t)) is the expected value of qi, given the observed data and
the current values of the parameters of interest. Completion of the E-step
requires the derivation of an expression for this expectation. Clearly, as qi is
an indicator variable, we have E(qi j Yobs; (t)) = P(qi = 1 j Yobs; (t)). Recall
that qi = 1 corresponds to an individual having a post-randomisation time to
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rst seizure that is censored, but exists. We can now formulate an expression
for E(qi j Yobs; (t)) as so:
E(qi j Yobs; (t)) = P(qi = 1 j Yobs; (t))
= p1iRY1(y1i;i;  1i; )
= p1i

1 +
i 1iy1i

 
:
The subsequent rst derivatives of Equation 6.6 are simple to obtain, allowing
the M-step, derivation of the maximum likelihood estimates of the parameters
contained in , to be carried out, using numerical methods.
We consider two versions of this model, the rst simply allows the cure rates
to depend on intercept terms, so that we consider only the overall cure rates,
across all individuals, for the times to rst seizure, and from rst to second
seizure post-randomisation. Following this, we shall allow the cure rates to
depend on statistically signicant covariates, using stepwise backwards elimi-
nation to evaluate the optimum model.
On tting the joint model that considers only the overall cure rates, across
all individuals, for each of the post-randomisation survival times, we obtain
maximum likelihood estimates for p1 and p2 of 0.478 (standard error 0.06) and
0.235 (standard error 0.11) respectively. Comparing both these estimates with
the Kaplan-Meier curves for time to rst seizure, these estimates seem sensible.
The formulation of this joint model allows us to formally test for the inclu-
sion of p1 and p2, comparing the subsequent log-likelihood with that of Joint
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Model B. A highly statistically signicant likelihood-ratio test statistic of 649
supports the inclusion of both cure rates. The maximum likelihood estimates
of p1 and p2 suggest that there is a substantial proportion of the population
`immune' to post-randomisation seizure recurrence, and a signicant propor-
tion who experience a single seizure post-randomisation `immune' to further
seizure recurrence. Also note that bp1 > bp2, which supports the conjecture that
seizures beget seizures, that is, the more seizures an individual has, the more
likely they are to continue experiencing seizures in the future.
The optimal joint model that considers the pre-randomisation event counts
and both post-randomisation survival times, with cure rates, was derived us-
ing stepwise backwards elimination. This model concluded that the parameters
statistically signicant in determining the cure rates associated with the times
to rst seizure were again seizure type, EEG outcome and their associated
interaction terms. Additionally, the optimal model found that treatment, and
its interaction with EEG outcome, were statistically signicant in determining
the probability of being `immune' to a rst seizure post-randomisation. There
were no covariates that were found to be statistically signicant in determining
the cure rates associated with the times from rst to second seizure.
Tables 6.5 and 6.6 show the estimated cure rates for times to rst seizure, and
the subsequent estimated seizure rate modiers for the susceptible proportion
respectively. Examination of Table 6.5 highlights that those individuals al-
located to deferred treatment, with an abnormal EEG, can expect to have
statistically signicantly lower cure rates than those with a normal EEG, ex-
cept for those individuals experiencing partial seizures only pre-randomisation,
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where no statistically signicant dierence is observed. For those with a normal
EEG, no statistically signicant treatment eect on the cure rates is observed.
Seizure Type 1  bp1i (95% C.I.)
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.537 (0.46,0.61) 0.365 (0.30,0.43)
2 Tonic-Clonic 0.398 (0.32,0.48) 0.247 (0.18,0.32)
Partial 0.500 (0.37,0.63) 0.331 (0.22,0.49)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.533 (0.47,0.59) 0.514 (0.46,0.57)
2 Tonic-Clonic 0.593 (0.52,0.66) 0.574 (0.50,0.64)
Partial 0.361 (0.22,0.54) 0.344 (0.20,0.52)
Table 6.5: The expected cure rates for the times to rst seizure, using the
estimated regression coecients from the joint model that incorporates the
post-randomisation times to rst seizure and from rst to second seizure, with
cure rates.
Recall that for times from rst to second seizure, the associated cure rate de-
pended on an intercept term only. The overall estimated cure rate was 24%.
Looking at the values of b i presented in Table 6.6, we again see that treatment
policy is not statistically signicant for those individuals with a normal EEG,
and once again, those individuals having an abnormal EEG, but allocated to
immediate treatment have a post-randomisation seizure rate in line with those
presenting a normal EEG. We can see that for those with an abnormal EEG,
immediate treatment is favoured. We again observe that the magnitudes of
the seizure rate reductions post-randomisation are not as large as those pre-
sented in Table 5.3. Additionally, note that a number of groups have a value
of b i not statistically signicantly dierent from unity, which corresponds to
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the seizure rate not changing post-randomisation.
Seizure Type b i (95% C.I.)
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.536 (0.41,0.69) 0.832 (0.66,1.04)
2 Tonic-Clonic 0.386 (0.30,0.50) 0.735 (0.58,0.94)
Partial 0.726 (0.47,1.13) 0.887 (0.58,1.35)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.701 (0.56,0.88) 0.746 (0.60,0.92)
2 Tonic-Clonic 0.663 (0.50,0.88) 0.866 (0.68,1.11)
Partial 0.743 (0.43,1.27) 0.622 (0.36,1.07)
Table 6.6: The expected change in seizure rates following randomisation for
the susceptible proportion, using the estimated regression coecients from the
joint model that incorporates the post-randomisation times to rst seizure and
from rst to second seizure, with cure rates.
6.3 Building a Full Model that Incorporates
Varying Post-Randomisation Seizure Rates
and Cure Rates
We now proceed to develop a model that jointly models the pre-randomisation
event counts and post-randomisation times to rst seizure, and from rst to
second seizure, incorporating both of the extensions that have already been
considered in isolation. That is, we shall develop a joint model that allows the
seizure rate to vary post-randomisation and incorporates cure rates for each
of the survival times.
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We assume that the pre-randomisation event count, for individual i, over pe-
riod ui, Xi, follows a Poisson distribution with mean and variance iuii, as
in the initial simple joint model. The probability density function for the
pre-randomisation event counts is given by
fXj(xi j i;i; ui) = (iuii)
xi exp( iuii)
xi!
:
The parameter i relates to the baseline covariates, with additional hetero-
geneity in the population being modelled through i, again assumed to follow
a Gamma(; ) distribution.
The probability density functions and survivor functions for the times to rst
seizure, and from rst to second seizure post-randomisation, are specied by
the following equations:
fY1j(y1i j i;i;  1i; p1i) = p1igY1j(y1i j i;i;  1i)
= p1ii 1ii exp( i 1iiy1i);
SY1j(y1i j i;i;  1i; p1i) = 1  p1i + p1iRY1j(y1i j i;i;  1i)
= 1  p1i + p1i exp( i 1iiy1i);
fY2j(y2i j i;i;  1i;  2i; p2i) = p2igY2j(y2i j i;i;  1i;  2i)
= p2ii 1i 2ii exp( i 1i 2iiy1i);
SY2j(y2i j i;i;  1i;  2i; p2i) = 1  p2i + p2iRY2j(y2i j i;i;  1i;  2i)
= 1  p2i + p2i exp( i 1i 2iiy2i):
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The density and survivor functions for the susceptibles are given by g() and
R() respectively. The term pji represents the probability that individual i is
susceptible to post-randomisation seizure j, so that 1 pji is the cure fraction.
The following parameterisations for p1i and p2i are considered:
p1i =
exp(01w1i)
1 + exp(01w1i)
;
p2i =
exp(02w2i)
1 + exp(02w2i)
:
Additionally, i = exp(
0
1z1i),  1i = exp(
0
2z2i),  2i = exp(
0
3z3i) and z1i, z2i,
z3i, w1i, w2i are vectors of covariates, not necessarily distinct.
6.3.1 Marginal Distributions
If the random eect term is integrated out of the joint density of Xi and
i, then the resulting unconditional density, fX(xi;i; ui; ), is, as before, the
Negative Binomial (Equation 4.1). The unconditional joint distribution of the
Yji, j = 1; 2, for the susceptible proportion, obtained when the random eects
are integrated out of gY1;Y2j(y1i; y2i j i;i;  1i;  2i), the joint density of the
survival times, Y1i and Y2i, and i, is the bivariate Lomax distribution.
The marginal distribution of Y1i, for those that are susceptible, is the uni-
variate Lomax distribution with shape and scale parameters  and =i 1i
respectively. The marginal distribution of Y2i, for those that are suscepti-
ble, is also the univariate Lomax distribution, but now with shape and scale
parameters  and =i 1i 2i respectively.
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6.3.2 The Full Log-Likelihood and Derivatives
When formulating the likelihood we need to consider the dierent ways that
censoring can occur. There are four dierent ways censoring can arise in this
setting, namely: (i) Y1i and Y2i are both observed, (ii) Y1i is observed, but
Y2i is censored, (iii) Y1i is censored, but exists, so Y2i is taken to be censored
at zero, and (iv) Y1i is censored, and cured, so Y2i does not exist. We now
consider these four situations separately:
Joint Distribution with Y1i and Y2i Observed
In this situation the joint density of Y1i and Y2i contributes towards the like-
lihood, giving
Z 1
0
fXj(xi j i;i; ui)p1ip2igY1;Y2j(y1i; y2i j i;i;  1i;  2i)f(i;)di
=
(iui)
xi
xi!
p1ip2i 2i(i 1i)
2 (xi + + 2)
 ()(iui + i 1i(y1i +  2iy2i) + )xi++2
: (6.7)
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Joint Distribution with Y1i Observed and Y2i Censored
In this situation the density function of Y1i and survivor functions of Y2i con-
tribute to the likelihood, giving
Z 1
0
fXj(xi j i;i; ui)p1igY1j(y1i j i;i;  1i)(1  p2i
+p2iRY2j(y2i j i;i;  1i;  2i))f(i;)di
=
(iui)
xi
xi!
p1ip2ii 1i
 (xi + + 1)
 ()

1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1

: (6.8)
Joint Distribution with Y1i Censored but Exists
In this scenario only the survivor function of Y1i contributes towards the like-
lihood, giving
Z 1
0
fXj(xi j i;i; ui)p1iRY1j(y1i j i;i;  1i)f(i;)di
=
(iui)
xi
xi!
p1i

 ()
 (xi + )
(iui + i 1iy1i + )xi+
: (6.9)
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Joint Distribution with Y1i Censored and Cured
In this scenario we only have the pre-randomisation event counts and random
eects for each individual, with the cure rate associated with the time to rst
seizure post-randomisation:
Z 1
0
fXj(xi j i;i; ui)(1  p1i)f(i;)di
=
(iui)
xi
xi!
(1  p1i)
 ()
 (xi + )
(iui + )xi+
: (6.10)
Log-likelihood
Let ji be the indicator function for the jth survival time, taking the value 1 if
the seizure is observed, and zero if the survival time is censored. Additionally,
we consider an allocation variable, qi, which is an indicator function taking the
value 1 if the individual is susceptible to post-randomisation seizure recurrence,
and zero if the individual is immune. Combining these indicator functions with
equations (6.7)-(6.10) allows us to formulate the log-likelihood for the observed
data D, for all the n individuals, given by
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`(;1;2;3;1;2 j D) =
nX
i=1
 xi 1X
k=0
ln(+ k)

+ xi ln(ui)  ln(xi!)
+ ln() + (xi + 1i(1 + 2i)) ln(i) + 1i(1 + 2i) ln( 1i) + 1i2i ln( 2i)
+1i ln(p1i) + 1i2i ln(p2i) + 1i ln(xi + ) + 1i2i ln(xi + + 1)
 1i2i(xi + + 2) ln(iui + i 1i(y1i +  2iy2i) + )
+(1  1i)qi ln

p1i
(iui + i 1iy1i + )xi+

+(1  1i)(1  qi) ln

1  p1i
(iui + )xi+

+1i(1  2i) ln

1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1

: (6.11)
As before, we do not observe the allocation variable, qi, for each individual,
instead we again regard it as a missing value and perform likelihood inference
in the presence of missing data. We adopt the EM-algorithm, implementing
the algorithm outlined in x 6.2.4.
Equation 6.11 is the complete-data log-likelihood, from which we can derive
the subsequent Q(; (t)) = E[ln(L( j Yobs; Ymis))]. Again we have
E(qi j Yobs; (t)) = p1i

1 +
i 1iy1i

 
:
The rst derivatives of the complete-data log-likelihood are straightforward to
derive, allowing subsequent maximisation using standard numerical methods.
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First Derivatives
The rst-order derivatives of the complete-data log-likelihood are
@`
@1
=
nX
i=1

xi + 1i(1 + 2i)  1i2i(xi + + 2)(iui + i 1i(y1i +  2iy2i))
iui + i 1i(y1i +  2iy2i) + 
 (1  1i)(xi + )

qi(iui + i 1iy1i)
iui + i 1iy1i + 
+
(1  qi)iui
iui + 

 1i(1  2i)(xi + + 1)

(1  p2i)(iui + i 1iy1i)
(iui + i 1iy1i + )xi++2
+
p2i(iui + i 1i(y1i +  2iy2i))
(iui + i 1i(y1i +  2iy2i) + )xi++2

1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1
 1
z1i;
@`
@2
=
nX
i=1

1i(1 + 2i)  1i2i(xi + + 2)i 1i(y1i +  2iy2i)
iui + i 1i(y1i +  2iy2i) + 
 (1  1i)(xi + )qii 1iy1i
iui + i 1iy1i + 
 1i(1  2i)(xi + + 1)

(1  p2i)i 1iy1i
(iui + i 1iy1i + )xi++2
+
p2ii 1i(y1i +  2iy2i)
(iui + i 1i(y1i +  2iy2i) + )xi++2

1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1
 1
z2i;
@`
@3
=
nX
i=1

1i2i   1i2i(xi + + 2)i 1i 2iy2i
iui + i 1i(y1i +  2iy2i) + 
  1i(1  2i)(xi + + 1)p2ii 1i 2iy2i
(iui + i 1i(y1i +  2iy2i) + )xi++2

1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1
 1
z3i;
@`
@1
=
nX
i=1

(1  p1i)  (1  1i)(1  qi)

w1i;
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@`
@2
=
nX
i=1

1i2i(1  p2i)  1i(1  2i)p2i(1  p2i)


1
(iui + i 1iy1i + )xi++1
  1
(iui + i 1i(y1i +  2iy2i) + )xi++1



1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1
 1
w2i;
@`
@
=
nX
i=1
 xi 1X
k=0
1
+ k

+
1i
xi + 
+
1i2i
xi + + 1
+ ln() + 1
 1i2i ln(iui + i 1i(y1i +  2iy2i) + )
  1i2i(xi + + 2)
iui + i 1i(y1i +  2iy2i) + 
 (1  1i)qi

xi + 
iui + i 1iy1i + 
+ ln(iui + i 1iy1i + )

 (1  1i)(1  qi)

xi + 
iui + 
+ ln(iui + )

 1i(1  2i)

xi + + 1
iui + i 1iy1i + 
+ ln(iui + i 1iy1i + )

 1  p2i
(iui + i 1iy1i + )xi++1
+

xi + + 1
iui + i 1i(y1i +  2iy2i) + 
+ ln(iui + i 1i(y1i +  2iy2i) + )

 p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1



1  p2i
(iui + i 1iy1i + )xi++1
+
p2i
(iui + i 1i(y1i +  2iy2i) + )xi++1
 1
:
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6.4 Implementing the Full Joint Model
Tables 6.7 and 6.8 give the estimated regression coecients for the full joint
model. The reference group contains individuals with partial seizures pre-
randomisation, with a normal EEG and randomised to deferred treatment.
A  regression coecient > 0 (< 0) would indicate an increased (decreased)
seizure rate relative to the seizure rate in the reference group. A  regression
coecient > 0 (< 0) would indicate an increase (decrease) in the susceptible
proportion relative to the susceptible proportion in the reference group and,
therefore, a subsequent decrease (increase) in the corresponding cure rate.
We can see that the regression coecients in i are similar to those observed in
Table 5.1 for Joint Model A and Joint Model B. This is not surprising as the ex-
tensions considered in this chapter are concerned with the post-randomisation
seizure rates, rather than the pre-randomisation seizure rates.
The value of  we observe in Table 6.7 is larger than the value observed in
Table 5.1. This increase in  indicates that there is less natural heterogeneity
in the full joint model than in the simple joint models developed in Chapter
5. This is increase in  is unsurprising as the inclusion of more covariates
explains more of the observed variation between individuals.
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Regression Estimates
Coecient (standard errors)
 2.023 (0.107)
i 1;0 -4.131 (0.086)
1;t c -1.076 (0.096)
1;2t c -0.701 (0.098)
1;partial reference
 1i 2;0 -0.958 (0.320)
2;trt 0.307 (0.347)
2;t c 0.577 (0.334)
2;2t c 0.483 (0.344)
2;partial reference
2;eeg 0.595 (0.350)
2;t ctrt -0.468 (0.352)
2;2t ctrt -0.594 (0.362)
2;partialtrt reference
2;eegtrt -0.593 (0.202)
2;t ceeg -0.518 (0.363)
2;2t ceeg -0.361 (0.374)
2;partialeeg reference
 2i 3;0 1.537 (0.524)
3;trt -0.393 (0.537)
3;t c -1.219 (0.544)
3;2t c -0.590 (0.551)
3;partial reference
3;eeg -0.820 (0.545)
3;t ctrt 0.599 (0.549)
3;2t ctrt 0.450 (0.555)
3;partialtrt reference
3;eegtrt 0.690 (0.315)
3;t ceeg 0.944 (0.564)
3;2t ceeg -0.266 (0.573)
3;partialeeg reference
Table 6.7: Estimated regression coecients in i,  1i and  2i for the full joint
model. The term i contains parameter estimates corresponding to the eect
of covariates on the underlying event rate. The terms  1i and  2i contain
parameter estimates corresponding to the eect of covariates on the post-
randomisation reduction in event rates at randomisation and following a rst
seizure post-randomisation respectively.
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Stepwise backwards elimination was used to derive the optimal full joint model,
which concluded that treatment policy, seizure type, EEG outcome and their
interactions were important in determining the change in seizure rate at ran-
domisation and following a rst seizure post-randomisation. Treatment policy
and seizure type were statistically signicant in determining the proportion im-
mune from seizure recurrence post-randomisation, as was EEG outcome and
its interactions with treatment policy and seizure type. No covariate eects
were statistically signicant in determining the cure rate for a second post-
randomisation seizure, this term was found to be dependent on an intercept
term only.
Wald tests were carried out on each of the estimated regression coecients,
and concluded that seizure type is statistically signicant in determining the
underlying, pre-randomisation seizure rates. Only 2;eegtrt is found to be
statistically signicant when considering the change in seizure rate following
randomisation. When looking at those explanatory variables corresponding
with the change in seizure rate following a seizure post-randomisation, we see
that only 3;t c and 3;eegtrt are statistically signicant.
When looking at the regression coecients in Table 6.8 we see that seizure
type is statistically signicant in determining whether an individual is suscep-
tible to seizure recurrence post-randomisation. Additionally 1;2t ceeg and
1;eegtrt are statistically signicant in determining the cure rates associated
with the times to rst seizure post-randomisation. For the cure rates asso-
ciated with the times from rst to second seizure post-randomisation, recall
that no statistically signicant covariate eects were observed.
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Regression Estimates
Coecient (standard errors)
p1i 1;0 0.706 (0.359)
1;trt -0.067 (0.146)
1;t c -0.750 (0.365)
1;2t c -0.979 (0.374)
1;partial reference
1;eeg -0.006 (0.448)
1;eegtrt -0.582 (0.228)
1;t ceeg 0.624 (0.458)
1;2t ceeg 1.378 (0.478)
1;partialeeg reference
p2i 2;0 1.037 (0.099)
-Log-likelihood (d.f.) 10855 (1301)
Table 6.8: Estimated regression coecients in p1i and p2i for the full joint
model. The term p1i contains parameter estimates corresponding to the eect
of covariates on the cure rate for the rst seizure post-randomisation. The term
p2i contains parameter estimates corresponding to the eect of covariates on
the cure rate for the second seizure post-randomisation.
6.4.1 Interpretation of the Results
To gain a better understanding of the estimated regression coecients, given in
Tables 6.7 and 6.8, we can obtain subsequent estimates of the cure rates and
the pre and post-randomisation seizure rates for the dierent seizure types,
EEG outcomes and treatment policies.
Table 6.9 shows that those individuals with a normal EEG, presenting with
partial seizures can expect to have a cure rate of around 30%, irrespective of
treatment policy, whilst those with tonic-clonic seizures can expect to have a
cure rate of around 50%. For those with an abnormal EEG, higher cure rates
are observed for those individuals randomised to immediate treatment, rather
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than deferred. Recall that Warrell et al. (2003) put seizure recurrence after a
single untreated seizure at around 80%, but Berg and Shinnar (1991) stated
that seizure recurrence was 50%. The results that we have observed in Table
6.9 may provide an explanation for the dierence in these values.
Seizure Type 1  bp1i (95% C.I.)
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.518 (0.45,0.59) 0.360 (0.20,0.43)
2 Tonic-Clonic 0.389 (0.31,0.48) 0.250 (0.19,0.33)
Partial 0.487 (0.36,0.62) 0.332 (0.22,0.46)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.528 (0.47,0.59) 0.511 (0.45,0.57)
2 Tonic-Clonic 0.584 (0.51,0.65) 0.568 (0.50,0.64)
Partial 0.345 (0.20,0.52) 0.330 (0.19,0.50)
Table 6.9: The expected cure rates associated with the post-randomisation
times to rst seizure, using the estimated regression coecients from the full
joint model.
Recall that no signicant covariate eects were observed for the cure rate as-
sociated with the times from rst to second seizure. The overall cure rate for
this survival time is 26%.
Table 6.10 shows the maximum likelihood estimates of  1i and  2i under the
full joint model. The values of b 1i represent the change in seizure rate fol-
lowing randomisation, with b 2i representing the change in rate following rst
post-randomisation seizure. We again see that treatment policy does not ap-
pear to be statistically signicant in determining the estimate of b 1i for those
individuals with a normal EEG. Additionally, for those individuals with an
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abnormal EEG, immediate treatment is favoured.
Seizure Type b 1i (95% C.I.) rst seizure
Abnormal EEG
Immediate Deferred
Tonic-Clonic 0.347 (0.26,0.47) 0.738 (0.57,0.95)
2 Tonic-Clonic 0.326 (0.24,0.44) 0.786 (0.58,1.06)
Partial 0.522 (0.31,0.88) 0.695 (0.41,1.18)
Normal EEG
Immediate Deferred
Tonic-Clonic 0.582 (0.45,0.75) 0.683 (0.53,0.87)
2 Tonic-Clonic 0.467 (0.34,0.65) 0.622 (0.46,0.84)
Partial 0.522 (0.27,1.00) 0.384 (0.20,0.73)b 2i (95% C.I.) second seizure
Abnormal EEG
Immediate Deferred
Tonic-Clonic 3.806 (2.43,5.97) 1.554 (1.00,2.41)
2 Tonic-Clonic 1.835 (1.17,2.88) 0.870 (0.56,1.36)
Partial 2.754 (1.17,6.49) 2.047 (0.98,4.26)
Normal EEG
Immediate Deferred
Tonic-Clonic 1.688 (1.13,2.51) 1.373 (0.93,2.02)
2 Tonic-Clonic 2.727 (1.69,4.41) 2.577 (1.67,3.97)
Partial 3.138 (1.28,7.70) 4.649 (1.63,13.27)
Table 6.10: The expected change in seizure rates following randomisation and
following the rst post-randomisation seizure, using the estimated regression
coecients from the full joint model.
Following a rst seizure post-randomisation we again see that, in general,
seizure rates increase. We observe that those individuals allocated to immedi-
ate treatment see more of an increase in seizure rate following a rst seizure
post-randomisation than those allocated to deferred treatment. Recall that
a possible explanation for this may be that those allocated to deferred treat-
ment may subsequently be started on a course of AEDs following a seizure
post-randomisation, bringing them in line with those allocated to immediate
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treatment. Also note that these individuals typically experience the smallest
reduction in seizure rate following randomisation.
6.5 Discussion
This chapter has examined extensions to the simple joint model that was de-
veloped in Chapter 5, both in isolation, and together in a single full model.
The simple joint model assumed that, post-randomisation, an individual's
seizure rate remained constant. This assumption was relaxed and a model
was considered that allowed the seizure rate to change both at randomisa-
tion, and following a rst post-randomisation seizure. We let  1i and  2i
be the seizure rate modiers at randomisation and following a rst post-
randomisation seizure respectively. We found that seizure rates were gen-
erally reduced after randomisation, but then increased following a rst post-
randomisation seizure. The change in seizure rates both at randomisation and
following a rst post-randomisation seizure were found to be dependent on
seizure type, treatment policy and EEG outcome.
We next considered the use of cure rate models in analysing the MESS data.
Standard statistical software exists for the implementation of Log-logistic mix-
ture survival models, that allow for the existence of cure rates. This model was
considered for the times to rst seizure and from rst to second seizure sepa-
rately. Initial models, that allowed the cure rates to depend on an intercept
term only, concluded that there was highly statistically signicant evidence to
support the inclusion of cure rates in modelling. Further investigation found
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that the cure rates associated with time to rst seizure post-randomisation
were dependent on seizure type, EEG outcome and the logarithm of an indi-
vidual's pre-randomisation seizure rate. For the cure rates associated with the
post-randomisation times from rst to second seizure however, no statistically
signicant covariate eects were found.
A model that jointly analysed the pre-randomisation event counts and post-
randomisation times to rst seizure only, with cure rates, was included for
completeness. A joint model for the pre-randomisation event counts and both
of the post-randomisation survival times, allowing each of the survival times
to have an associated cure rate, was then considered. It was noted that if
an individual's time to rst seizure post-randomisation is censored, it is un-
known whether censoring is due to the individual being `immune' to seizures
post-randomisation, or due to their period of follow up not being sucient to
observe the survival time. An unobserved allocation variable was introduced
to distinguish between these two scenarios and the EM-algorithm was adopted
for the maximisation of the subsequent log-likelihood.
The optimal joint model that considers the pre-randomisation event counts
and both post-randomisation survival times, with cure rates, concluded that
those individuals allocated to deferred treatment, with an abnormal EEG,
can expect to have statistically signicantly lower cure rates than those with
a normal EEG, except for those individuals experiencing partial seizures only
pre-randomisation, where no statistically signicant dierence is observed. For
those with a normal EEG, no statistically signicant treatment eect on the
cure rates was observed. There were no covariates that were found to be sta-
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tistically signicant in determining the cure rates associated with the times
from rst to second seizure.
After considering each of the extensions applicable to the MESS data in
isolation, a model was developed that allows the pre-randomisation event
counts and post-randomisation times to rst seizure, and from rst to sec-
ond seizure to be analysed jointly. This full joint model allowed the seizure
rate to vary post-randomisation and incorporated cure rates for each of the
post-randomisation survival times.
Those individuals with a normal EEG, presenting with partial seizures can ex-
pect to have a cure rate of around 30%, irrespective of treatment policy, whilst
those with tonic-clonic seizures can expect to have a cure rate of around 50%.
For those with an abnormal EEG, higher cure rates are observed for those
individuals randomised to immediate treatment rather than deferred. No sta-
tistically signicant covariate eects were concluded in determining the cure
rate for a second post-randomisation seizure, this term was found to be de-
pendent on an intercept term only. Treatment policy was not statistically
signicant in determining the estimate of the change in seizure rate following
randomisation, for those individuals with a normal EEG. For those individu-
als with an abnormal EEG, immediate treatment was favoured. Following a
rst seizure post-randomisation we observed a general increase in seizure rates,
however, those allocated to deferred treatment, possibly surprisingly, have the
smallest increase in seizure rate following a rst seizure post-randomisation.
Possible explanations for this observation were discussed.
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Chapter 7
Model Checking
This thesis discusses the use of joint models for event counts and survival
times as an alternative to standard survival models. Chapter 5 developed a
simple joint model that had more statistically signicant covariate eects than
standard survival analysis. Further investigation of the subsequent estimated
pre-randomisation seizure rates and post-randomisation seizure rate modiers,
however, highlighted possible limitations to the model.
Chapter 6 considered each of the interesting characteristics, present in the
data, separately and together in a nal full joint model. This full joint model
allowed the pre-randomisation event counts and post-randomisation times to
rst seizure and from rst to second seizure to be analysed together. Fur-
thermore, this full joint model assumed a change in seizure rate both at ran-
domisation and following a rst post-randomisation seizure, with each of the
survival times having an associated proportion cured.
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This chapter will assess the performance of this full joint model, compared
with standard survival analysis, by investigating how well the distribution of
the survival times is modelled under the dierent models considered.
7.1 Kaplan-Meier Curves
We will present a number of Kaplan-Meier curves along with the subsequent
tted estimates of survival, using the nal full joint model that was devel-
oped in Chapter 6. These survival curves will be compared to the estimated
survival curves obtained through implementing the standard survival methods.
It has already been noted that standard software (Peng ) exists that allows for
the analysis of survival data using the Log-logistic model with cure rates. We
therefore use the estimates obtained from the Log-logistic mixture model, that
incorporated a cure fraction, to produce tted survival curves for the times
to rst seizure, and from rst to second seizure post-randomisation. The esti-
mated survivor functions are derived using
bSYj(yji;ji; j; pji) = 1  bpji + bpji(1 + (bjiyji)bj) 1; j = 1; 2;
where in each model bji = exp(b0jdi) for a vector bj of estimated regression
coecients for survival time j, and a vector di of covariates for each individual
i. The parameter bj > 0 is the estimated shape parameter associated with
survival time j.
The term bpji represents the estimated susceptible proportion associated with
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survival time j post-randomisation, so that 1  bpji is the estimated cure frac-
tion. The following parameterisations for bp1i and bp2i are considered:
bp1i = exp(b01w1i)
1 + exp(b01w1i) ;bp2i = exp(b02w2i)
1 + exp(b02w2i) :
The estimated Log-logistic tted survival curves will be compared with the
tted estimates of survival obtained using the full joint model that allows the
seizure rate to vary post-randomisation, and incorporates cure rates for each
of the survival times. Log-likelihood ratio tests concluded that the full joint
model, presented in x 6.3, was the optimal model for analysing the MESS
data. Stepwise backwards elimination was used to determine which explana-
tory variables were statistically signicant in the model. The estimated sur-
vivor functions for the survival times, under the full joint model are given
by
bSY1(y1i;i;  1i; ; p1i) = 1  bp1i + bp1i1 + bi b 1iy1ib
 b
;
bSY1(y1i;i;  1i;  2i; ; p2i) = 1  bp2i + bp2i1 + bi b 1i b 2iy2ib
 b
:
Additionally, bi = exp(b01z1i), b 1i = exp(b02z2i), b 2i = exp(b03z3i), where b1,b2 and b3 are vectors of estimated regression coecients and z1i, z2i, z3i are
vectors of covariates, not necessarily distinct.
We will examine the Kaplan-Meier and tted estimates of the survival curves
for dierent subgroups of individuals in our dataset. We conne our investi-
gation of the survival curves to those individuals presenting with secondary
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tonic-clonic seizures only pre-randomisation. We then consider four dierent
scenarios for these individuals separately:
 Normal EEG and allocated to immediate treatment.
 Normal EEG and allocated to deferred treatment.
 Abnormal EEG and allocated to immediate treatment.
 Abnormal EEG and allocated to deferred treatment.
Recall that the standard survival analysis of the MESS data included the
logarithm of an individual's pre-randomisation seizure rate as an explana-
tory variable in determining their subsequent times to rst seizure and from
rst to second seizure. In the subsequent derivation of the estimated tted
survival curves we shall just consider the mean of the logarithm of the pre-
randomisation seizure rates for each individual.
Figures 7.1-7.4 present the Kaplan-Meier estimates of the survival curves, for
each of the subgroups considered, with their corresponding 95% condence
intervals. The estimated tted survival curves from the two parametric mod-
els considered are also presented. We can see that for times to rst seizure,
and from rst to second seizure, for each of the subgroups, the tted full joint
model, and the tted Log-logistic survival model with cure rates, both seem
to model the distribution of survival very well. We observed that for the most
part, the estimates of the tted survival curves for the full joint model, and
Log-logistic model with cure rates, tend to remain within the 95% condence
intervals of the corresponding Kaplan-Meier estimates.
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Figure 7.1: Kaplan-Meier curves and tted curves for time to rst seizure,
and time from rst to second seizure, for those with an abnormal EEG and
allocated to immediate treatment.
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Figure 7.2: Kaplan-Meier curves and tted curves for time to rst seizure,
and time from rst to second seizure, for those with an abnormal EEG and
allocated to deferred treatment.
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Figure 7.3: Kaplan-Meier curves and tted curves for time to rst seizure, and
time from rst to second seizure, for those with a normal EEG and allocated
to immediate treatment.
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Figure 7.4: Kaplan-Meier curves and tted curves for time to rst seizure, and
time from rst to second seizure, for those with a normal EEG and allocated
to deferred treatment.
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7.2 Goodness-of-Fit
A method for testing goodness-of-t of parametric distributions to survival
data was developed by Maller and Zhou (1996), which is a variant to the
method devised by Filliben (1975) for testing the normality of uncensored
data. Filliben (1975) proposed calculating the correlation coecient between
the order statistics of a sample and the expected values of the order statistics
for a sample of the same size from a standard Normal distribution. The subse-
quent correlation coecient then forms the basis of the test, with values close
to 1 being indicative of a good t and values close to zero suggesting a poor t.
The test for censored survival times introduced by Maller and Zhou (1996)
considers the hypothesis H0 : F = bF , where bF is some specied distribution
function. Let y1  y2  : : :  yn be the ordered sample of survival times.
If there is no censoring present, then a plot of bF (yji) against the empirical
distribution function, ~F (yji) = i=n, under H0, should produce a near-straight
line with slope close to 1. When censoring is present the same argument would
lead us to expect to obtain, under H0, a near-straight line with slope close to
1, by plotting bF (yji) = 1   bS(yji) against ~F (yji), where ~F is taken as the
Kaplan-Meier estimate.
Figures 7.5-7.8 present plots of the estimated Kaplan-Meier estimates of the
cumulative distribution function of the survival times, against the correspond-
ing tted estimates for the parametric models considered.
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Figure 7.5: Kaplan-Meier estimate and tted estimates of the cumulative dis-
tribution function for time to rst seizure, and time from rst to second seizure,
for those with an abnormal EEG and allocated to immediate treatment.
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Figure 7.6: Kaplan-Meier estimate and tted estimates of the cumulative dis-
tribution function for time to rst seizure, and time from rst to second seizure,
for those with an abnormal EEG and allocated to deferred treatment.
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Figure 7.7: Kaplan-Meier estimate and tted estimates of the cumulative dis-
tribution function for time to rst seizure, and time from rst to second seizure,
for those with a normal EEG and allocated to immediate treatment.
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Figure 7.8: Kaplan-Meier estimate and tted estimates of the cumulative dis-
tribution function for time to rst seizure, and time from rst to second seizure,
for those with a normal EEG and allocated to deferred treatment.
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The gures suggest that the joint model performs very well when considering
the times to rst seizure post-randomisation. The Log-logistic distribution,
with cure rates, however, generally appears to model the survival times from
rst to second seizure better.
Maller and Zhou (1996) propose using the correlation coecient, r, between
~F (yji) and F^ (yji), 1  i  n as an appropriate measure of the goodness-of-
t. The correlation coecient however, is a measure of a linear relationship
between two sets of data, this is not necessarily useful when trying to assess
the goodness of t. We do not wish to assess the strength of linearity between
~F (yji) and F^ (yji), we wish to test how far the points deviate from the line of
equality.
7.3 Discussion
We have formally shown that the full joint model performs very well when
considering how well the distribution of the survival times is modelled. We
have shown, however, that the Log-logistic distribution is also very good at
modelling the distribution of the survival times. Comparisons between the two
models have simply comprised of a visual examination of Figures 7.1-7.8. No
formal comparisons between the full joint model and the standard Log-logistic
survival model, with cure rates, have been carried out.
We have not formally assessed the performance of the full joint model in its
own right. Maller and Zhou (1996) propose using the correlation coecient as
a means of testing model performance. We have noted however, that correla-
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tion coecients are used to assess the strength of a linear relationship between
two sets of data. We wish to assess the strength of equality between two sets
of data which renders the correlation coecient unsuitable.
To assess model performance more accurately, we propose that a statistic
which assesses the levels of deviations from equality of two sets of data needs
to be derived.
133
Chapter 8
Further Extensions Applicable
to MESS
We shall now present further analyses of the MESS data that could be consid-
ered, but that are not carried out in this thesis. We develop a zero-truncated,
one-inated Poisson distribution for the pre-randomisation count data as an
alternative to the standard Poisson distribution. We discuss analyses that
consider the type of AED an individual is assigned and include further post-
randomisation survival times. We also consider the analysis of long-term prog-
nosis.
8.1 Zero-Truncated, One-Inated Poisson Dis-
tribution
It has already been noted that over half of the participants recruited to MESS
presented only a single seizure pre-randomisation. This excess of ones that
the data displays is not accounted for in any of the models considered in
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this thesis. Additionally, recall that the eligibility criterion for the MESS
trial specied that participants should have had at least one epileptic seizure
pre-randomisation. A one-inated, zero-truncated Poisson distribution could
therefore be considered for the pre-randomisation event counts. The zero-
truncated Poisson is a model for count data that is truncated at zero (Finney
and Varley 1955). The density function for the zero-truncated Poisson(iuii)
distribution is
ZTP(xi;i; ui; i) =
(iuii)
xi exp( iuii)
xi!(1  exp( iuii)) =
(iuii)
xi
xi!(exp(iuii)  1) :
The one-inated, zero-truncated Poisson distribution is a model for data that
exhibits excess ones and is truncated at zero. The model assumes that, with
probability , the only possible observation is 1, and with probability 1   a
zero-truncated Poisson(iuii) random variable is observed. Hence,
Xi = 1 with probability  + (1  ) iuii
(exp(iuii)  1) ;
Xi = k > 1 with probability (1  ) (iuii)
k
k!(exp(iuii)  1) ;
giving, for xi  1,
fX(xi;i; ui; i; ) = I[xi=1] + (1  )ZTP(xi;iuii); (8.1)
where I[xi=1] is the indicator function taking the value 1 when xi = 1 and zero
otherwise.
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8.2 Dierent Antiepileptic Drugs
MESS was initially designed to investigate the dierence between two policies:
immediate versus deferred treatment. The randomisation scheme was reevalu-
ated part way through the trial, allowing the relative merits of specic drugs to
be investigated. Consequently, during the trial, two randomisation procedures
were utilised. Initially the clinicians declared which drug a patient would be
administered only if they were allocated to immediate treatment. A conse-
quence of this randomisation scheme is that for those individuals randomised
to deferred treatment, it is not known what drug they would have been given
had they been randomised to immediate treatment. Subsequently, any analy-
sis conned to a particular drug using this data will be potentially confounded.
Part way through the trial the randomisation scheme was altered so that clin-
icians had to declare which drug would be most appropriate for participants
prior to randomisation. Specifying the drug prior to randomisation creates
control groups for individual drugs, but analysing only those individuals that
allow for comparisons within specic drugs ignores a substantial amount of
costly data. Of the 1425 individuals considered in the exploratory analysis,
614 were randomised using the rst randomisation scheme, leaving 811 ran-
domised using the second, updated scheme. We propose adopting missing data
techniques to complete the data matrix, allowing analysis across all individu-
als, subsequently giving more reliable results.
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8.2.1 Multiple Imputation
Our data exhibits univariate non-response, as missingness is conned to a sin-
gle variable, namely the type of drug a patient was assigned at randomisation.
One strategy for handling missing data is to impute the missing values and
then use standard statistical methods on the completed data matrix. Suppose
there are two variables ZJ and ZK , and suppose further that ZJ is completely
observed, but some of the ZK are missing. If the two variables are strongly
correlated it may be sensible to use ZJ to predict those values of ZK that are
missing. Methods of this type can be used to impute either single or multiple
values for each of the missing items, producing complete data matrices which
can then be analysed using standard techniques. One method of imputation is
regression imputation, which replaces missing values by predicted values from
a regression of the missing item on items observed for the unit.
In the case of epilepsy, the drug a patient is assigned is strongly dependent
on a number of the baseline covariates that were collected in the MESS trial,
namely age, sex and covariates concerning the type of epilepsy a patient has
and the nature of the seizures. This would enable us to use regression im-
putation methods, regressing the missing items on those inuential baseline
covariates we have observed, which, in turn, should allow us to approach the
interesting question of dierences between specic drug types.
We have already presented a brief discussion of multiple imputation (MI) in
Chapter 2. Recall that MI is the term given to the procedure of replacing
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missing values by D  2 imputed values. This policy produces D complete
data sets, and standard statistical techniques can be used to analyse each of
these. If the D sets of imputations are repeated random draws from the same
predictive model the D complete-data inferences can be combined to form one
inference properly reecting the uncertainty caused by the nonresponse.
8.3 Inclusion of further Post-Randomisation
Survival Times
The outcomes concerning short-term seizure recurrence, that were measured
in the MESS trial, were times to rst, second and fth seizures. However,
owing to the fact that we have the raw data, it may be possible, and more
informative, to establish times to the intermittent third and fourth seizures.
For example, if a second seizure is observed, but the fth seizure censored,
we do not know if this censoring occurred before the third, fourth or fth
seizure. Hence, consideration of the raw data would boost the quality of the
data we were working with. It would then be useful to generalise the model
we have developed to allow for the joint modelling of the pre-randomisation
event counts and a general m number of post-randomisation survival times.
8.4 Analysis of Long-Term Prognosis
In studies of epilepsy, interest is often not restricted to the analysis of the risk
of short-term seizure recurrence, but also the long-term prognosis. The MESS
trial was conducted to assess not only short-term outcomes, times to one and
two year remission were also considered.
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Figure 8.1 shows the Kaplan-Meier curves for the times to one and two year re-
mission, stratied by treatment policy. Additionally, the Kaplan-Meier curves
are marked at each censoring time which is not also a death time.
Standard analysis would ignore the rst sections of the plots in Figure 8.1
and simply report the percentage of people achieving one year and two year
remission at 365 and 730 days respectively. Marson et al. (2005) discusses
time to two year remission and simply reports that at two years 64% of those
in the immediate treatment group and 52% in the deferred group achieved
immediate remission, further discussing how this dierence diminishes in time.
Figure 8.1 shows substantial drop-out within the rst one and two years. An
immediate consequence of this is that the percentages presented will be exag-
gerated. For example, Marson et al. (2005) interpret their reported 64% as
the percentage of patients randomised achieving immediate remission. What
that gure actually represents is the percentage of people randomised who
have either achieved immediate remission at two years, or have dropped out of
the trial within the two years. An analysis that does not take this into consid-
eration may give misleading results. The reasons for drop-out could include a
patient being randomised to deferred treatment and not experiencing a further
seizure, hence regarding follow-up as pointless, but could also include patients
moving house, or death. Clearly careful investigation of patient drop-out must
be considered.
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Figure 8.1: Kaplan-Meier plots of the times to one and two remission.
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8.5 Discussion
This chapter has outlined some further extensions that could be considered
in the analysis of the MESS dataset. Firstly, a zero-truncated, one-inated
Poisson distribution was proposed as an alternative to the standard Poisson
distribution. This distribution accounts for the fact that all patients included
in the MESS trial had to have had at least one clinically denite, unprovoked
epileptic seizure prior to randomisation, and that over half of those included
presented with only a single seizure pre-randomisation.
Two randomisation procedures were used in the MESS trial, initially a clin-
ician would declare which drug a patient were to receive only if they were
randomised to immediate treatment. The second randomisation procedure,
implemented around half way through the recruitment of patients, required
clinicians to declare which drug a patient would receive, prior to randomisa-
tion to a treatment policy. The second of these randomisation policies allows
comparisons between the dierent AEDs to be carried out. For those individ-
uals randomised using the rst treatment policy, it is proposed that missing
data methods are adopted to recover information missing about subsequent
choices of AEDs.
Outcomes of the MESS trial, not included in the analyses presented in this
thesis, are time to fth seizure and times to one and two year remission. It
is proposed that times to third and fourth seizure may be obtainable from
the raw data, allowing the joint model to be generalised, to jointly model pre-
randomisation event counts and a general number of m post-randomisation
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survival times. Investigation into the eects of treatment policy on the long-
term prognosis of epilepsy may also be carried out.
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Chapter 9
Conclusions
9.1 Overview of Thesis
This thesis has built a number of models that can be used to analyse data
that arrive in the form of event counts, and survival times, following a change
in event rate. Chapter 3 provided an overview of the epilepsy dataset which
motivated the statistical models that have been developed in this thesis. Non-
parametric analyses of the data were carried out and non-parametric estimates
of the survivor functions, for the two survival times, were transformed in order
to provide an indication as to which parametric model may be suitable for
further analyses.
In Chapter 4 standard parametric analyses of the pre-randomisation event
counts and post-randomisation times to rst seizure, and from rst to sec-
ond seizure were presented. Following the analysis of each of the outcomes
separately, a joint model was developed in Chapter 5 that allowed the pre-
randomisation event counts and post-randomisation survival times to be anal-
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ysed in a single model. This joint model comprised a simple extension of the
model developed by Cowling et al. (2006). This simple joint model was used
in the analysis of the MESS data, and was found to be superior to standard
survival techniques. Further examination of the estimated pre-randomisation
seizure rates, and post-randomisation seizure rate modications indicated that
there may be interesting characteristics within the MESS data, not accounted
for in the simple joint model.
It was proposed in Chapter 6 that the assumption of a constant seizure rate
post-randomisation may not be accurate. There was evidence to suggest that
cure rates may be present in the dataset, this was also investigated in Chap-
ter 6. After examining each of these extensions to the simple joint model in
isolation, a full joint model that incorporated both of the extensions was de-
veloped. This joint model allowed the seizure rate to vary post-randomisation
and incorporated cure rates for each of the survival times.
Chapter 7 assessed the performance of the full joint model, compared with
standard survival analysis, by investigating how well the distribution of the
survival times is modelled under the dierent models considered. The Kaplan-
Meier estimates of the survival curves were examined alongside the tted es-
timates of survival for the two parametric models considered.
9.2 Conclusions about Epilepsy Data
We can see that those individuals presenting with partial seizures only pre-
randomisation typically experience the highest seizure rates. Those experienc-
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ing tonic-clonic seizures only and secondary tonic-clonic seizures have statis-
tically signicantly lower rates.
For the cure rates associated with the times to rst seizure post-randomisation,
treatment policy has no eect for those individuals presenting with a normal
EEG. Those individuals with a normal EEG, presenting with partial seizures
can expect to have a cure rate of around 30%, irrespective of treatment pol-
icy, whilst those with tonic-clonic seizures can expect to have a cure rate of
around 50%. For those with an abnormal EEG, higher cure rates are observed
for those individuals randomised to immediate treatment, rather than deferred.
The optimal full joint model concluded that no explanatory variables were
statistically signicant in determining the cure rates associated with the times
from rst to second seizure post-randomisation. The overall estimated cure
rate for these survival times was 26%.
When considering the estimated values of the seizure rate modiers follow-
ing randomisation, we conclude that treatment policy does not appear to
be statistically signicant for those individuals with a normal EEG. Those
with an abnormal EEG, but allocated to immediate treatment have estimated
post-randomisation seizure rate modiers in line with those presenting with a
normal EEG. Additionally, for those individuals with an abnormal EEG and
allocated to deferred treatment, the seizure rate modiers following randomi-
sation are generally not statistically dierent from unity, which is indicative
of no change in seizure rate post-randomisation.
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Following a rst seizure post-randomisation we see that, in general, seizure
rates increase. We observe that those individuals allocated to immediate treat-
ment see a more substantial increase in seizure rate following a rst seizure
post-randomisation than those allocated to deferred treatment. This contrast
is greater for those with an abnormal EEG. It has been proposed that a pos-
sible explanation for this is that those allocated to deferred treatment may
subsequently start a course of AEDs following a seizure post-randomisation,
bringing them in line with those allocated to immediate treatment. Also note
that those individuals with an abnormal EEG and allocated to deferred treat-
ment typically experience the smallest reduction in seizure rate following ran-
domisation.
9.3 Conclusions about the Joint Models
We shall provide an overview of the assumptions that were made in the simple
joint model. We shall also discuss how the model was extended to accommo-
date those assumptions that were violated in the MESS data. We shall also
provide an overview of additional assumptions that are made in all of the joint
models that have been developed in this thesis.
9.3.1 Assumptions in the Simple Joint Model
The simple joint model, developed in Chapter 5, assumed that individuals ex-
perience seizures according to a Poisson process, so that the pre-randomisation
event counts follow a Poisson distribution and interevent times are Exponen-
tial. Each individual that was recruited to MESS had an underlying baseline
seizure rate, which was updated at randomisation to allow for treatment ef-
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fects. This simple joint model was used to analyse the MESS data, which
subsequently cast doubt on assumptions that had been made.
Secondly, note that the simple joint model assumed that post-randomisation,
seizure rates remained constant. It has been stated that clinicians believe
that epileptic seizures beget epileptic seizures, that is, the more seizures an
individual presents with, the more likely they are to carry on having seizures,
with increased frequency. We also noted that, following the implementation
of the simple joint model, the estimated regression coecients observed in
Joint Model B were closer to zero than those estimates observed in Joint
Model A. This result has suggested that the assumption of a constant post-
randomisation seizure rate may be violated.
The simple joint model assumed that, post-randomisation, everyone in the
sample was susceptible to seizure recurrence. We know that seizure recur-
rence following a single untreated seizure is around 50%  80%, and as MESS
was a study of early epilepsy it was not unreasonable to assume that a pro-
portion of individuals included in the trial would be `immune' from seizure
recurrence post-randomisation. The magnitude of the seizure rate reductions
observed following the implementation of the simple joint model highlighted
that if survival data does indeed have a proportion that are immune to the
event of interest, considering a proper survival model that ignores this, may
give misleading results.
This thesis proceeded to address each of the assumptions discussed above rst
in isolation, and then together, in a full joint model.
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9.3.2 Violation of the Post-Randomisation Survival Time
IID Assumption
It was proposed that seizure rates may change not only at randomisation, but
also following a rst seizure post-randomisation. We considered a joint model
that included seizure rate modiers, both at randomisation and following a
rst post-randomisation seizure, and allowed these terms to depend on a num-
ber of explanatory variables.
We observed that at randomisation seizure rates either did not change, or
decreased and following a rst seizure post-randomisation, we saw that, in
general, seizure rates increased.
9.3.3 Incorporation of Cure Rates
The magnitude of the reductions in seizure rates post-randomisation, observed
in Chapter 5, suggested that there may be a substantial proportion of the pop-
ulation that we should regard as cured. Additionally, the Kaplan-Meier curves
for each of the post-randomisation survival times have their asymptotes well
above zero. This suggested that there may be an immune component present
in the MESS data for both times to rst seizure post-randomisation and from
rst to second seizure.
Models were developed that allowed for the inclusion of cure rates for each
of the survival times.
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9.3.4 Further Assumptions
Cowling (2003) outlines some of the assumptions made when developing a
joint model that considers pre-randomisation event counts and a single post-
randomisation survival time. Some of the assumptions associated with this
joint model are also relevant when we consider the joint models that have
been developed in this thesis.
First, all of the joint models assume that the seizure rate between successive
seizures remains constant. Clinical opinion, however, is that following a seizure
there is an instantaneous increase in the risk of future seizures, which is why
we typically observe clustering of seizures. Recall that Figure 3.3 displayed
the empirical cumulative distribution function for Y1=T2, and showed that for
those experiencing at least two seizures post-randomisation, their time from
rst seizure to second was typically shorter than their time from randomisa-
tion to rst seizure. It is thought that the immediate increase in risk following
a seizure diminishes in time, but that in some cases of epilepsy the condition
deteriorates after each event occurs. In the full joint model that we have de-
veloped, we have simply assumed that seizure rates change after each event,
remaining constant between events. We may need to consider the possibility
that seizure rates also change between events.
A further assumption that has been made is that there is an instantaneous
multiplicative treatment eect at randomisation. Recall that MESS was a
pragmatic trial, meaning that recruited individuals received treatment with
AEDs in line with the clinicians' usual practice. When patients start a course
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of AEDs, they typically start with smaller doses for an initial period, rather
than starting immediately on the full dose. A consequence of this is that we
may observe a delayed treatment eect which would need to be accounted for.
9.3.5 Further Work
Chapter 8 outlined further possible extensions to the analysis of the MESS
data, that have been considered, but not carried out in this thesis. A zero-
truncated, one-inated Poisson distribution has been proposed as an alterna-
tive to the standard Poisson distribution, to reect the fact that all individuals
entering the trial had experienced at least one seizure pre-randomisation, al-
though many presented with a single seizure only.
It was proposed that missing data methods could be adopted to recover infor-
mation about the specic types of AED that were administered. This informa-
tion could then be included as an explanatory variable in analyses. Additional
outcomes that could be considered are times to third, fourth and fth seizure
post-randomisation, and times to one and two year remission.
One of the big questions in epilepsy is what causes drug refractoriness. We
have stated in this thesis that around 30% of epilepsy suerers will never
achieve long-term remission from epileptic seizures. Clinical opinion is that
there may be genetic determinants of this, as well as clinical ones. Epilepsy
data exists that considers the outcomes time to rst seizure and time to 12
month remission. This epilepsy dataset additionally contains information on
individuals' DNA. It has been proposed that the models we have developed in
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this thesis may be applicable to the analysis of this data.
Chapter 7 compared the performance of the full joint model with the Log-
logistic model that incorporated cure rates, by considering how well the tted
estimates modelled the distribution of the survival curves. This comparison,
however, did not formally assess the performance of the full joint model in its
own right. Maller and Zhou (1996) propose using the correlation coecient,
for the Kaplan-Meier estimates of the cumulative distribution function and
the corresponding tted estimates from the full joint model, as a means of
testing model performance. We have noted however, that correlation coe-
cients would simply assess the strength of a linear relationship between these
two sets of data, but we wish to assess the strength of equality. Further work
may consider statistics that may be appropriate for this.
9.4 Summary
In conclusion, this thesis has developed a number of statistical models that can
be used in the analysis of data that arrives in the form of pre-randomisation
event counts and two post-randomisation survival times. These joint models
have been motivated by and illustrated on epilepsy data. The nal full joint
model that was concluded as optimal has been compared with standard sur-
vival models that incorporated cure rates. Despite initial indications being
that the full joint model was superior to standard modelling strategies, vi-
sual comparisons of how the well the tted estimates model the distribution
of the survival times have shown that standard methods also perform very well.
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It would be interesting to explore further if there are certain scenarios whereby
the full joint model provides a signicant improvement over standard survival
methods.
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Appendix A
Lomax Survival Distribution
Standard software for the analysis of survival data using the Lomax distri-
bution does not exist. By considering the density and survivor functions of
the Lomax distribution, we can derive the log-likelihood. First and second
derivatives of this log-likelihood can easily be obtained, allowing inference on
the parameters  and , using a numerical method such as Newton Raphson.
A.1 The Full Log-Likelihood and Derivatives
Recall that the probability density function for the Lomax distribution is
fY (yi;i; ) = i
 
 + iyi
+1
; (A.1)
where i = exp(
0di) for a vector  of regression coecients, and a vector di
of covariates for each individual i, including an intercept term. It is trivial
to derive the corresponding survivor function from the probability density
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function:
SY (yi;i; ) =
Z 1
yi
fY (u;i; )du
=
 
 + iyi

: (A.2)
Log-likelihood
Let i be the indicator function for the survival time, taking the value 1 if
the seizure is observed, and zero if the survival time is censored. Combining
these indicator functions with density and survivor functions, (A.1) and (A.2)
respectively, allows us to formulate the log-likelihood for the observed data D
on all the n individuals, given by
`(; j D) =
nX
i=1
fi ln fY (yi;i; ) + (1  i) lnSY (yi;i; )g
=
nX
i=1
fi ln(i) + (i + ) ln()  (i + ) ln( + iyi)g:(A.3)
First Derivatives
The rst-order derivatives of the full log-likelihood, (A.3) are:
@`
@
=
nX
i=1

(i   iyi)
 + iyi

di
@`
@
=
nX
i=1

ln() + 1 +
i

  ln( + iyi)  i + 
 + iyi

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Second Derivatives
The second-order derivatives of the full log-likelihood are:
@2`
@@0 =  
nX
i=1

iyi(i + )
( + iyi)2

didi0
@2`
@@0 =  
nX
i=1

1

  i
2
  1
 + iyi
+
i   iyi
( + iyi)2

@2`
@@
=
nX
i=1

iyi(i   iyi)
( + iyi)2

di
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Appendix B
R Code
B.1 Simple Joint Model
joint1 <- function(alphainit = 1, beta1initvec = 0, beta2initvec
= c(0, 0), incl1 = 1, incl2 = 1, data, maxiter = 50)
{
#
# Function to find maximum likelihood estimates for joint model
# Data should be in a data frame including:
# "nseiz" = pre-randomisation seizure count;
# "period" = period in days from first pre-randomisation
# seizure to randomisation
# "time1" = post-randomisation time to first seizure;
# "time2" = post-randomisation time from first seizure
# to second seizure;
# "cens1" = censoring indicator (first seizure);
# "cens2" = censoring indicator (second seizure);
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# "type1" 0/1 tonic-clonic seizures only pre-randomisation;
# "type2" 0/1 partial with 2-degree t-c pre-randomisation;
# "type3" 0/1 generalised seizures pre-randomisation
# (including tonic-clonic and generalised);
# "type4" 0/1 partial minor seizures only pre-randomisation;
# "type6" 0/1 other seizures pre-randomisation;
# "ager" = age at randomisation minus 30 as a continuous
# covariate in years;
# "sex" 0/1 indicating sex (male/female);
# "trt" 0/1 indicating treatment (deferred/immediate).
# "eeg" 0/1 indicating eeg outcome (normal/abnormal);
#
# When calling the function, "incl1" and "incl2" decide which
# covariates to include in lambda and psi respectively.
#
#
# the first section initialises the variables in the model
#
k1 <- length(beta1initvec)
k2 <- length(beta2initvec)
beta1out <- matrix(rep(NA, k1 * maxiter), ncol = k1)
beta2out <- matrix(rep(NA, k2 * maxiter), ncol = k2)
alphaout <- matrix(rep(NA, maxiter), ncol = 1)
beta1out[1, ] <- beta1initvec
beta2out[1, ] <- beta2initvec
alphaout[1, ] <- alphainit
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maxx <- 1
i <- 1
#
#
# the next section is a Newton-Raphson loop, repeatedly calling
# the function "joint2" until every estimate is within 0.00001
# of its value in the previous iteration
#
#
while((i <= maxiter - 1) && (maxx > 1e-005)) {
i <- i + 1
newests <- joint2(alphaout[i - 1, ], beta1out[i - 1,
], beta2out[i - 1, ], incl1, incl2, data)
alphaout[i, ] <- newests$alpha
beta1out[i, ] <- newests$beta1
beta2out[i, ] <- newests$beta2
maxad <- abs(alphaout[i, ] - alphaout[i - 1, ])
maxbd1 <- max(abs(beta1out[i, ] - beta1out[i - 1, ]))
maxbd2 <- max(abs(beta2out[i, ] - beta2out[i - 1, ]))
maxx <- max(maxad, maxbd1, maxbd2)
}
#
#
# the final section uses the maximum likelihood solution to
# generate the variance-covariance matrix (also using "joint2")
# and then output the estimates and related information
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##
newcov <- joint2(alphaout[i, ], beta1out[i, ], beta2out[i,
], incl1, incl2, data)
list(alpha = alphaout[i, ], beta1 = beta1out[i, ], beta2
= beta2out[i, ], sd = round(sqrt(diag(newcov$covmat)),
digits = 3), wald = round(c(beta1out[i, ],beta2out[i,
])^2/diag(newcov$covmat)[-1],
digits = 3), covmat = newcov$covmat, iter = i, loglik
= newcov$loglik)
}
joint2 <- function(alpha, beta1vec, beta2vec, incl1,incl2, data)
{
#
# Function to help "joint1" by finding the log-likelihood,
# gradient, and Hessian, for a single Newton-Raphson iteration
#
# The first section initialises some parameters for the model,
# and reparameterises some covariates
#
k1 <- length(beta1vec)
k2 <- length(beta2vec)
n <- length(data$type1)
beta1 <- matrix(beta1vec, nrow = k1)
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beta2 <- matrix(beta2vec, nrow = k2)
ager <- data$ager
type1 <- data$type1
type2 <- data$type2
type3 <- data$type3
type4 <- data$type4
type6 <- data$type6
trt <- data$trt
eeg <- data$eeg
sex <- data$sex
trttype1 <- trt * type1 # trt/type interactions
trttype2 <- trt * type2
trttype3 <- trt * type3
trttype4 <- trt * type4
trttype6 <- trt * type6
trtager <- trt * ager
eegtype1 <- eeg * type1 # eeg/type interactions
eegtype2 <- eeg * type2
eegtype3 <- eeg * type3
eegtype4 <- eeg * type4
eegtype6 <- eeg * type6
trteeg <- trt * eeg
cens1 <- data$cens1
time1 <- data$time1
cens2 <- data$cens2
time2 <- data$time2
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nseiz <- data$nseiz
period <- data$period
#
#
# the next section uses the initially specified variables "incl1"
# and "incl2" to construct the covariate matrices which will
# later be used to give lambda and psi
#
#
if(incl1 == 1)
z1 <- matrix(rep(1, n), byrow = T, nrow = k1)
if(incl1 == 2)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6),
byrow = T, nrow = k1)
if(incl1 == 3)
z1 <- matrix(c(rep(1, n), ager), byrow = T, nrow = k1)
if(incl1 == 4)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6,
ager),
byrow = T, nrow = k1)
if(incl1 == 5)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6,
ager, sex), byrow = T, nrow = k1)
if(incl1 == 6)
z1 <- matrix(c(rep(1, n), type1, type2),
byrow = T, nrow = k1)
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#if(incl2 == 0)
z2 <- matrix(rep(1, n), byrow = T, nrow = k2)
if(incl2 == 1)
z2 <- matrix(c(rep(1, n), trt), byrow = T, nrow = k2)
if(incl2 == 2)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6), byrow = T, nrow = k2)
if(incl2 == 3)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager), byrow = T, nrow = k2)
if(incl2 == 4)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager, eeg), byrow = T, nrow = k2)
if(incl2 == 5)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, eeg), byrow = T, nrow = k2)
if(incl2 == 6)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, trttype1, trttype2, trttype3, trttype6,
eeg, trteeg, eegtype1, eegtype2, eegtype3,
eegtype6), byrow = T, nrow = k2)
if(incl2 == 7)
z2 <- matrix(c(rep(1, n), trt, type1, type2),
byrow = T, nrow = k2)
if(incl2 == 8)
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z2 <- matrix(c(rep(1, n), trt, type1, type2,
trttype1, trttype2, eeg, trteeg, eegtype1,
eegtype2), byrow = T, nrow = k2)
#
#
# the next section initialises the matrices and vectors
# which will store the values of the likelihood contributions,
# and the contributions to the gradient and Hessian, for
# each individual observation
#
#
mat1 <- matrix(rep(0, k1 * k1), nrow = k1) # for the Hessian
mat2 <- matrix(rep(0, k2 * k2), nrow = k2) # for the Hessian
mat12 <- matrix(rep(0, k1 * k2), nrow = k1) # for the Hessian
mat1a <- matrix(rep(0, k1), nrow = k1) # for the Hessian
mat2a <- matrix(rep(0, k2), nrow = k2) # for the Hessian
#
term1 <- matrix(rep(0, k1), nrow = k1) # for the gradient
term2 <- matrix(rep(0, k2), nrow = k2) # for the gradient
#
bigmat <- matrix(rep(0, (k1 + k2 + 1) * (k1 + k2 + 1)),
nrow = k1 + k2 + 1)
invbigmat <- bigmat # for the observed information matrix
#
aterm1 <- rep(NA, n) # for the Hessian
aterm2 <- aterm1 # for the gradient
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aterm3 <- rep(0, n)
aterm4 <- aterm3
#
ll <- rep(NA, n)
llterm1 <- rep(0, n)
#
lambda <- exp(t(beta1) %*% z1) # individual rate
psi <- exp(t(beta2) %*% z2) # treatment effect
#
cens <- cens1 * (1 + cens2)
time <- time1 + time2
bit1 <- lambda * period
bit2 <- lambda * psi * time
bit3 <- bit1 + bit2 + alpha #these "bits" come up a lot
#
#
# the next section is a loop for each observation in the data,
# calculating the individual contribution to the log-likelihood,
# the gradient, and the Hessian
#
#
for(i in 1:n) {
#
# for Hessian and gradient contributions for beta1 and beta2
#
mat1 <- mat1 - ((alpha * (nseiz[i] + cens[i] + alpha) *
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(bit1[i] + bit2[i]))/(bit3[i] * bit3[i])) * outer(
z1[, i], z1[, i])
mat2 <- mat2 - (((nseiz[i] + alpha + cens[i]) * (bit1[i]
+ alpha) * bit2[i])/(bit3[i] * bit3[i])) * outer(
z2[, i], z2[, i])
mat12 <- mat12 - ((alpha * (alpha + nseiz[i] + cens[i])
* bit2[i])/(bit3[i] * bit3[i])) * outer(z1[, i],
z2[, i])
#
term1 <- term1 + ((alpha * (nseiz[i] + cens[i] -
bit1[i] - bit2[i]))/bit3[i]) * z1[, i]
term2 <- term2 + ((cens[i] * bit1[i] - nseiz[i] * bit2[i]
+ alpha * (cens[i] - bit2[i]))/bit3[i]) * z2[, i]
#
# for gradient and Hessian contributions for alpha
#
for(j in 0:(nseiz[i] - 1)) {
aterm3[i] <- aterm3[i] + 1/((alpha + j)^
2)
aterm4[i] <- aterm4[i] + 1/(alpha + j)
}
aterm1[i] <- aterm3[i] + (cens1[i]/((alpha + nseiz[i]) *
(alpha + nseiz[i]))) + ((cens1[i] * cens2[i])/
((alpha + nseiz[i] + 1) * (alpha + nseiz[i] + 1))) -
(1/alpha) - ((nseiz[i] + cens[i] - alpha - 2 *
(bit1[i] + bit2[i]))/(bit3[i] * bit3[i]))
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aterm2[i] <- aterm4[i] + (cens1[i]/(alpha + nseiz[i])) +
((cens1[i] * cens2[i])/(alpha + nseiz[i] + 1)) +
log(alpha) + 1 - log(bit3[i]) - ((nseiz[i] +
alpha + cens[i])/bit3[i])
#
# for Hessian contribution of correlation between alpha and beta
#
mat1a <- mat1a + (((bit1[i] + bit2[i]) * (nseiz[i] +
cens[i] - bit1[i] - bit2[i]))/(bit3[i] * bit3[i])) *
z1[, i]
mat2a <- mat2a + (((nseiz[i] + cens[i] - bit1[i] -
bit2[i]) * bit2[i])/(bit3[i] * bit3[i])) * z2[, i]
#
# for log-likelihood contribution of individual i
#
for(j in 0:(nseiz[i] - 1)) {
llterm1[i] <- llterm1[i] + log(alpha +
j)
}
ll[i] <- llterm1[i] + cens1[i] * log(alpha + nseiz[i]) +
(cens1[i] * cens2[i]) * log(alpha + nseiz[i] + 1) +
nseiz[i] * log(period[i]) + alpha * log(alpha) +
(nseiz[i] + cens[i]) * log(lambda[i]) + cens[i] *
log(psi[i]) - lgamma(nseiz[i] + 1) - (nseiz[i] +
alpha + cens[i]) * log(bit3[i])
}
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##
# the next section combines the individual second-derivative
# matrices into the Hessian, and then the observed information
# matrix.
#
#
bigmat[2:(k1 + 1), 2:(k1 + 1)] <- mat1
bigmat[2:(k1 + 1), (k1 + 2):(k1 + k2 + 1)] <- mat12
bigmat[(k1 + 2):(k1 + k2 + 1), 2:(k1 + 1)] <- t(mat12)
bigmat[(k1 + 2):(k1 + k2 + 1), (k1 + 2):(k1 + k2 + 1)] <-
mat2
bigmat[1, 1] <- 0 - sum(aterm1)
bigmat[1, 2:(k1 + 1)] <- mat1a
bigmat[1, (k1 + 2):(k1 + k2 + 1)] <- mat2a
bigmat[2:(k1 + 1), 1] <- t(mat1a)
bigmat[(k1 + 2):(k1 + k2 + 1), 1] <- t(mat2a)
#
invbigmat <- solve(bigmat)
#
#
# the final section finds the updated parameter estimates using
# a Newton-Raphson step, and outputs the new parameter values,
# the observed information matrix, and the fitted log-likelihood
#
#
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newabvec <- t(c(alpha, beta1, beta2) - invbigmat %*% c(sum(
aterm2), term1, term2))
#
list(alpha = newabvec[, 1], beta1 = newabvec[, 2:(k1 + 1)],
beta2 = newabvec[, (k1 + 2):(k1 + k2 + 1)], covmat = -
invbigmat, loglik = sum(ll))
}
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B.2 Full Model
two_cure_rate1 <- function(alphainit, beta1init, beta2init,
beta3init, kappa1init, kappa2init, incl1, incl2, incl5, incl3,
incl4, data, maxiter = 50, iterations=500)
{
#
# the first section initialises the variables in the model
#
#
k1 <- length(beta1init)
k2 <- length(beta2init)
k3 <- length(kappa1init)
k4 <- length(kappa2init)
k5 <- length(beta3init)
beta1out <- matrix(rep(NA, k1 * maxiter), ncol = k1)
beta2out <- matrix(rep(NA, k2 * maxiter), ncol = k2)
beta3out <- matrix(rep(NA, k5 * maxiter), ncol = k5)
kappa1out <- matrix(rep(NA, k3 * maxiter), ncol = k3)
kappa2out <- matrix(rep(NA, k4 * maxiter), ncol = k4)
alphaout <- matrix(rep(NA, maxiter), ncol = 1)
beta1out[1, ] <- beta1init
beta2out[1, ] <- beta2init
kappa1out[1, ] <- kappa1init
kappa2out[1, ] <- kappa2init
alphaout[1, ] <- alphainit
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beta3out[1, ] <- beta3init
maxx <- 1
i <- 1
#
#
# the next section is an optim loop, repeatedly calling
# the function "two_cure2" until every estimate is within
# 0.00001 of its value in the previous iteration
#
#
while((i <= maxiter - 1) && (maxx > 1e-005)) {
i <- i + 1
newests <- two_cure_rate2(alphaout[i - 1, ], beta1out[i
- 1, ], beta2out[i - 1, ], beta3out[i - 1, ],
kappa1out[i - 1, ], kappa2out[i - 1, ], incl1,
incl2, incl5, incl3, incl4, data, iterations)
alphaout[i, ] <- newests$alpha
beta1out[i, ] <- newests$beta1
beta2out[i, ] <- newests$beta2
beta3out[i, ] <- newests$beta3
kappa1out[i, ] <- newests$kappa1
kappa2out[i, ] <- newests$kappa2
maxad <- abs(alphaout[i, ] - alphaout[i - 1, ])
maxbd1 <- max(abs(beta1out[i, ] - beta1out[i - 1, ]))
maxbd2 <- max(abs(beta2out[i, ] - beta2out[i - 1, ]))
maxbd3 <- max(abs(beta3out[i, ] - beta3out[i - 1, ]))
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maxkd1 <- max(abs(kappa1out[i, ] - kappa1out[i - 1,
]))
maxkd2 <- max(abs(kappa2out[i, ] - kappa2out[i - 1,
]))
maxx <- max(maxad, maxbd1, maxbd2, maxbd3, maxkd1,
maxkd2)
}
#
#
# the final section uses the maximum likelihood solution to
# generate the variance-covariance matrix (also using
# "two_cure2") and then output the estimates and related
# information
#
#
newcov <- two_cure_rate2(alphaout[i, ], beta1out[i, ],
beta2out[i, ], beta3out[i, ], kappa1out[i, ],
kappa2out[i, ], incl1, incl2, incl5, incl3, incl4,
data, iterations)
list(alpha = alphaout[i, ], beta1 = beta1out[i, ], beta2 =
beta2out[i, ], beta3 = beta3out[i, ], kappa1 =
kappa1out[i, ], kappa2 = kappa2out[i, ], sd =
round(sqrt(diag(newcov$covmat)),digits = 3), wald =
round(c(beta1out[i, ],beta2out[i, ],beta3out[i, ],
kappa1out[i, ], kappa2out[i, ])^2/diag(newcov$covmat)[
-1], digits = 3), covmat = newcov$covmat, iter = i,
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loglik = newcov$loglik)
}
two_cure_rate2 <- function(alphain, beta1vec, beta2vec,
beta3vec, kappa1vec, kappa2vec, incl1, incl2, incl5, incl3,
incl4, data, iterations)
{
#
# Function to help "two_cure1" by finding the log-likelihood,
# and gradient, for a single optim iteration
#
#
#
# the first section initialises some parameters for the model,
# and reparameterises some covariates
#
#
k1 <- length(beta1vec)
k2 <- length(beta2vec)
k3 <- length(kappa1vec)
k4 <- length(kappa2vec)
k5 <- length(beta3vec)
n <- length(data$type1)
ager <- data$ager
type1 <- data$type1
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type2 <- data$type2
type3 <- data$type3
type4 <- data$type4
type6 <- data$type6
trt <- data$trt
eeg <- data$eeg
sex <- data$sex
trttype1 <- trt * type1 # trt/type interactions
trttype2 <- trt * type2
trttype3 <- trt * type3
trttype4 <- trt * type4
trttype6 <- trt * type6
trtager <- trt * ager
eegtype1 <- eeg * type1 # eeg/type interactions
eegtype2 <- eeg * type2
eegtype3 <- eeg * type3
eegtype4 <- eeg * type4
eegtype6 <- eeg * type6
trteeg <- trt * eeg
cens1 <- data$cens1
time1 <- data$time1
cens2 <- data$cens2
time2 <- data$time2
nseiz <- data$nseiz
period <- data$period
#
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## the next section uses the initially specified variables "incl1"
# and "incl2" to construct the covariate matrices which will
# later be used to give lambda and psi
#
#
if(incl1 == 1)
z1 <- matrix(rep(1, n), byrow = T, nrow = k1)
if(incl1 == 2)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6),
byrow = T, nrow = k1)
if(incl1 == 3)
z1 <- matrix(c(rep(1, n), ager), byrow = T, nrow = k1)
if(incl1 == 4)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6,
ager), byrow = T, nrow = k1)
if(incl1 == 5)
z1 <- matrix(c(rep(1, n), type1, type2, type3, type6,
ager, sex), byrow = T, nrow = k1)
if(incl1 == 6)
z1 <- matrix(c(rep(1, n), type1, type2), byrow = T,
nrow = k1)
if(incl1 == 7)
z1 <- matrix(c(rep(1, n), type1, type3, type6),
byrow = T, nrow = k1)
#
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if(incl2 == 0)
z2 <- matrix(rep(1, n), byrow = T, nrow = k2)
if(incl2 == 1)
z2 <- matrix(c(rep(1, n), trt), byrow = T, nrow = k2)
if(incl2 == 2)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6), byrow = T, nrow = k2)
if(incl2 == 3)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager), byrow = T, nrow = k2)
if(incl2 == 4)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager, eeg), byrow = T, nrow = k2)
if(incl2 == 5)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, eeg), byrow = T, nrow = k2)
if(incl2 == 6)
z2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, trttype1, trttype2, trttype3, trttype6, eeg,
trteeg, eegtype1, eegtype2, eegtype3, eegtype6),
byrow = T, nrow = k2)
if(incl2 == 7)
z2 <- matrix(c(rep(1, n), trt, type1, type2), byrow = T,
nrow = k2)
if(incl2 == 8)
z2 <- matrix(c(rep(1, n), trt, type1, type2, trttype1,
175
trttype2, eeg, trteeg, eegtype1, eegtype2),
byrow = T, nrow = k2)
#
if(incl3 == 0)
w1 <- matrix(rep(1, n), byrow = T, nrow = k3)
if(incl3 == 1)
w1 <- matrix(c(rep(1, n), trt), byrow = T, nrow = k3)
if(incl3 == 2)
w1 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6), byrow = T, nrow = k3)
if(incl3 == 3)
w1 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager), byrow = T, nrow = k3)
if(incl3 == 4)
w1 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager, eeg), byrow = T, nrow = k3)
if(incl3 == 5)
w1 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, eeg), byrow = T, nrow = k3)
if(incl3 == 6)
w1 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, trttype1, trttype2, trttype3, trttype6, eeg,
trteeg, eegtype1, eegtype2, eegtype3, eegtype6),
byrow = T, nrow = k3)
if(incl3 == 7)
w1 <- matrix(c(rep(1, n), trt, type1, type2), byrow = T,
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nrow = k3)
if(incl3 == 8)
w1 <- matrix(c(rep(1, n), trt, type1, type2, trttype1,
trttype2, eeg, trteeg, eegtype1, eegtype2),
byrow = T, nrow = k3)
if(incl3 == 9)
w1 <- matrix(c(rep(1, n), type1, type2, eeg, eegtype1,
eegtype2), byrow = T, nrow = k3)
#
if(incl4 == 0)
w2 <- matrix(rep(1, n), byrow = T, nrow = k4)
if(incl4 == 1)
w2 <- matrix(c(rep(1, n), trt), byrow = T, nrow = k4)
if(incl4 == 2)
w2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6), byrow = T, nrow = k4)
if(incl4 == 3)
w2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager), byrow = T, nrow = k4)
if(incl4 == 4)
w2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager, eeg), byrow = T, nrow = k4)
if(incl4 == 5)
w2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, eeg), byrow = T, nrow = k4)
if(incl4 == 6)
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w2 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, trttype1, trttype2, trttype3, trttype6, eeg,
trteeg, eegtype1, eegtype2, eegtype3, eegtype6),
byrow = T, nrow = k4)
if(incl4 == 7)
w2 <- matrix(c(rep(1, n), trt, type1, type2), byrow = T,
nrow = k4)
if(incl4 == 8)
w2 <- matrix(c(rep(1, n), trt, type1, type2, trttype1,
trttype2, eeg, trteeg, eegtype1, eegtype2), byrow = T,
nrow = k4)
#
if(incl5 == 0)
z3 <- matrix(rep(1, n), byrow = T, nrow = k5)
if(incl5 == 1)
z3 <- matrix(c(rep(1, n), trt), byrow = T, nrow = k5)
if(incl5 == 2)
z3 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6), byrow = T, nrow = k5)
if(incl5 == 3)
z3 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager), byrow = T, nrow = k5)
if(incl5 == 4)
z3 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, ager, eeg), byrow = T, nrow = k5)
if(incl5 == 5)
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z3 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, eeg), byrow = T, nrow = k5)
if(incl5 == 6)
z3 <- matrix(c(rep(1, n), trt, type1, type2, type3,
type6, trttype1, trttype2, trttype3, trttype6, eeg,
trteeg, eegtype1, eegtype2, eegtype3, eegtype6),
byrow = T, nrow = k5)
if(incl5 == 7)
z3 <- matrix(c(rep(1, n), trt, type1, type2), byrow = T,
nrow = k5)
if(incl5 == 8)
z3 <- matrix(c(rep(1, n), trt, type1, type2, trttype1,
trttype2, eeg, trteeg, eegtype1, eegtype2),
byrow = T, nrow = k5)
#
#
#
#
lambdaq<-exp(t(beta1vec)%*%z1)
psiq<-exp(t(beta2vec)%*%z2)
p1q<-exp(t(kappa1vec)%*%w1)/(1+exp(t(kappa1vec)%*%w1))
alphaq<-alphain
q <- p1q * ((1 + (lambdaq * psiq * time1)/alphaq)^(-alphaq))
#
#
like <- function(par){
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alpha <- par[1]
beta1 <- matrix(par[2:(k1 + 1)], nrow = k1)
beta2 <- matrix(par[(k1 + 2):(k1 + k2 + 1)], nrow = k2)
beta3 <- matrix(par[(k1 + k2 + 2):(k1 + k2 + k5 + 1)],
nrow = k5)
kappa1 <- matrix(par[(k1 + k2 + k5 + 2):(k1 + k2 + k5 + k3
+ 1)], nrow = k3)
kappa2 <- matrix(par[(k1 + k2 + k5 + k3 + 2):(k1 + k2 + k5
+ k3 + k4 + 1)], nrow = k4)
#
ll <- rep(NA, n)
llterm1 <- rep(0, n)
#
lambda <- exp(t(beta1) %*% z1) # individual rate
psi1 <- exp(t(beta2) %*% z2) # treatment effect 1
psi2 <- exp(t(beta3) %*% z3) # treatment effect 2
p1 <- exp(t(kappa1) %*% w1)/(1 + exp(t(kappa1) %*% w1))
p2 <- exp(t(kappa2) %*% w2)/(1 + exp(t(kappa2) %*% w2))
# p is the susceptible proportion
#
cens <- cens1 * (1 + cens2)
bit1 <- lambda * period
bit2 <- lambda * psi1 * time1
bit3 <- lambda * psi1 * psi2 * time2
bit4 <- bit1 + bit2
bit5 <- bit3 + bit4
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bit6 <- nseiz + alpha
bit7 <- ((1 - p1)/((bit1 + alpha)^(bit6)))
bit8 <- (p1/((bit4 + alpha)^(bit6)))
bit9 <- ((1 - p2)/((bit4 + alpha)^(bit6 + 1))) + (p2/((bit5
+ alpha)^(bit6 + 1)))
# these "bits" come up a lot
#
#
for(i in 1:n) {
for(j in 0:(nseiz[i] - 1)) {
llterm1[i] <- llterm1[i] + log(alpha +
j)
}
ll[i] <- llterm1[i] + (nseiz[i] * log(period[i])) -
lgamma(nseiz[i] + 1) + (alpha * log(alpha)) + ((nseiz[i] +
cens[i]) * log(lambda[i])) + (cens[i] * log(psi1[i])) +
(cens1[i] * log(p1[i])) + (cens1[i] * cens2[i] * log(p2[i])) +
(cens1[i] * log(bit6[i])) + (cens1[i] * cens2[i] * log(bit6[i]
+ 1)) - (cens1[i] * cens2[i] * (bit6[i] + 2) * log(bit5[i] +
alpha)) + (cens1[i] * (1 - cens2[i]) * log(bit9[i])) + ((1 -
cens1[i]) * q[i] * log(bit8[i])) + ((1 - cens1[i]) * (1 - q[i])
* log(bit7[i])) + (cens1[i] * cens2[i] * log(psi2[i]))
}
return(sum(ll))
}
#
181
##
#
grad <- function(par){
alpha <- par[1]
beta1 <- matrix(par[2:(k1 + 1)], nrow = k1)
beta2 <- matrix(par[(k1 + 2):(k1 + k2 + 1)], nrow = k2)
beta3 <- matrix(par[(k1 + k2 + 2):(k1 + k2 + k5 + 1)],
nrow = k5)
kappa1 <- matrix(par[(k1 + k2 + k5 + 2):(k1 + k2 + k5 + k3
+ 1)], nrow = k3)
kappa2 <- matrix(par[(k1 + k2 + k5 + k3 + 2):(k1 + k2 + k5
+ k3 + k4 + 1)], nrow = k4)
#
term1 <- matrix(rep(0, k1), nrow = k1) # for the gradient
term2 <- matrix(rep(0, k2), nrow = k2) # for the gradient
term3 <- matrix(rep(0, k5), nrow = k5) # for the gradient
kterm1 <- matrix(rep(0, k3), nrow = k3) # for the gradient
kterm2 <- matrix(rep(0, k4), nrow = k4) # for the gradient
#
aterm1 <- rep(NA, n)
aterm2 <- rep(0, n) # for the gradient
#
lambda <- exp(t(beta1) %*% z1) # individual rate
psi1 <- exp(t(beta2) %*% z2) # treatment effect 1
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psi2 <- exp(t(beta3) %*% z3) # treatment effect 2
p1 <- exp(t(kappa1) %*% w1)/(1 + exp(t(kappa1) %*% w1))
p2 <- exp(t(kappa2) %*% w2)/(1 + exp(t(kappa2) %*% w2))
# p is the susceptible proportion
#
cens <- cens1 * (1 + cens2)
bit1 <- lambda * period
bit2 <- lambda * psi1 * time1
bit3 <- lambda * psi1 * psi2 * time2
bit4 <- bit1 + bit2
bit5 <- bit3 + bit4
bit6 <- nseiz + alpha
bit7 <- ((1 - p1)/((bit1 + alpha)^(bit6)))
bit8 <- (p1/((bit4 + alpha)^(bit6)))
bit9 <- ((1 - p2)/((bit4 + alpha)^(bit6 + 1))) + (p2/((bit5
+ alpha)^(bit6 + 1)))
# these "bits" come up a lot
#
#
for(i in 1:n) {
# for gradient contributions for beta1, beta2
#
term1 <- term1 + (nseiz[i] + cens[i] - ((cens1[i] *
cens2[i] * (bit6[i] + 2) * bit5[i])/(bit5[i] + alpha)) - ((1 -
cens1[i]) * bit6[i] * (((q[i] * bit4[i])/(bit4[i] + alpha)) +
(((1 - q[i]) * bit1[i])/(bit1[i] + alpha)))) - ((cens1[i] * (1 -
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cens2[i]) * (bit6[i] + 1) * ((((1 - p2[i]) * bit4[i])/((bit4[i]
+ alpha)^(bit6[i] + 2))) + ((p2[i] * bit5[i])/((bit5[i] + alpha)
^(bit6[i] + 2)))))/bit9[i])) * z1[, i]
#
term2 <- term2 + (cens[i] - ((cens1[i] * cens2[i] *
(bit6[i] + 2) * (bit2[i] + bit3[i]))/(bit5[i] + alpha)) -
(((1 - cens1[i]) * q[i] * bit6[i] * bit2[i])/(bit4[i] + alpha)) -
((cens1[i] * (1 - cens2[i]) * (bit6[i] + 1) * ((((1 - p2[i]) *
bit2[i])/((bit4[i] + alpha)^(bit6[i] + 2))) + ((p2[i] * (bit2[i]
+ bit3[i]))/((bit5[i] + alpha)^(bit6[i] + 2)))))/bit9[i])) *
z2[, i]
#
kterm1 <- kterm1 + ((1 - p1[i]) - ((1 - cens1[i]) * (1 - q[i])))
* w1[, i]
#
kterm2 <- kterm2 + (cens1[i] * cens2[i] * (1 - p2[i]) -
((cens1[i] * (1 - cens2[i]) * p2[i] * (1 - p2[i]) * (((bit4[i] +
alpha)^(- bit6[i] - 1)) - ((bit5[i] + alpha)^(- bit6[i] - 1))))/
bit9[i])) * w2[, i]
#
term3 <- term3 + ((cens1[i] * cens2[i]) - ((cens1[i] * cens2[i] *
(bit6[i] + 2) * bit3[i])/(bit5[i] + alpha)) - (((cens1[i] * (1 -
cens2[i]) * (bit6[i] + 1) * p2[i] * bit3[i])/((bit5[i] + alpha)^
(bit6[i] + 2)))/bit9[i])) * z3[, i]
#
# for gradient contributions for alpha
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#for(j in 0:(nseiz[i] - 1)) {
aterm2[i] <- aterm2[i] + 1/(alpha + j)
}
aterm1[i] <- aterm2[i] + log(alpha) + 1 + (cens1[i]/
bit6[i]) + ((cens1[i] * cens2[i])/(bit6[i] + 1)) - (cens1[i] *
cens2[i] *
log(bit5[i] + alpha)) - ((cens1[i] * cens2[i] * (bit6[i] +
2))/(bit5[i] + alpha)) - ((cens1[i] * (1 - cens2[i]) *
((((((bit6[i] + 1)/(bit4[i] + alpha)) + log(bit4[i] + alpha)) * (1 -
p2[i]))/((bit4[i] + alpha)^(bit6[i] + 1))) + (((((bit6[i] + 1)/
(bit5[i] + alpha)) + log(bit5[i] + alpha)) * p2[i])/((bit5[i] + alpha)^
(bit6[i]+ joint1)))))/bit9[i]) - ((1 - cens1[i]) * q[i] * ((bit6[i]/
(bit4[i] + alpha)) + log(bit4[i] + alpha))) - ((1 - cens1[i]) * (1 -
q[i]) * ((bit6[i]/(bit1[i] + alpha)) + log(bit1[i] + alpha)))
#
}
return(c(sum(aterm1),term1,term2,term3,kterm1,kterm2))
}
#
#
#
joint<-optim(c(alphain,beta1vec,beta2vec,beta3vec,kappa1vec,
kappa2vec),like,grad,hessian=T,method=`Nelder-Mead',
control=list(maxit=iterations,fnscale=-1))
#
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#alpha = joint$par[1]
beta1 = joint$par[2:(k1 + 1)]
beta2 = joint$par[(k1 + 2):(k1 + k2 + 1)]
beta3 = joint$par[(k1 + k2 + 2):(k1 + k2 + k5 + 1)]
kappa1 = joint$par[(k1 + k2 + k5 + 2):(k1 + k2 + k5 + k3 + 1)]
kappa2 = joint$par[(k1 + k2 + k5 + k3 + 2):(k1 + k2 + k5 + k3 +
k4 + 1)]
#
list(alpha = alpha, beta1 = beta1, beta2 = beta2, beta3 =
beta3, kappa1 = kappa1, kappa2 = kappa2, sd =
round(sqrt(diag(-solve(joint$hessian))),digits = 3), wald =
round(c(beta1,beta2,beta3,kappa1,kappa2)^2/diag(-solve(joint$hessian))[
-1],digits = 3),covmat = -solve(joint$hessian), loglik = joint$value,
convergence = joint$convergence, message = joint$message)
}
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Appendix C
Clinical Paper
In addition to the work that has been presented in this thesis, I have collabo-
rated with clinicians at the University of Liverpool. As part of this collabora-
tion, I am currently working on a clinical paper that analyses the MESS data,
but attention is focussed on post-randomisation times to rst seizure of any
type and rst tonic-clonic seizure. This paper is currently in the draft stage,
but I include a brief summary here1.
One of the most important decisions for a person with newly diagnosed epilep-
tic seizures will be whether to start treatment with an antiepileptic drug
(AED). This will be dependent on an analysis that requires consideration
of the risk of seizures on the one hand and the side eects associated AED
treatment on the other. Existing literature tends to focuss primarily on the
risks associated tonic-clonic seizures in patients who have presented with a
tonic clonic seizure previously. For patients who have received a diagnosis of
1The most up to date draft of the clinical paper discussed here can be found at
http://www.warwick.ac.uk/go/jenniferrogers/research/thesis.
This page is password protected, the password is `thesisrogers2010'.
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epilepsy, but have never experienced a tonic-clonic seizure, information about
the risk of future tonic-clonic seizures may be clinically relevant. The MRC
Multicentre Trial for Early Epilepsy and Single Seizures (MESS) was a ran-
domized controlled trial which compared the treatment policies of immediate
and deferred treatment with AEDs, in those patients considered to be in the
early stages of epilepsy. Because of its broad entry criteria, MESS contained
a number of patients with a history of partial seizures only. In this paper we
explore the outcomes time to rst seizure of any type and time to rst tonic-
clonic seizure in these patients, and compare them with that of other subjects
who had at least one tonic-clonic seizure before randomisation.
The data arrives in the two parts: a pre-randomisation seizure count, along
with the associated number of days over which these seizures were observed,
and post-randomisation survival times to rst seizure of any type and rst
tonic-clonic seizure. We adopt methodology that allows the pre-randomisation
seizure counts and post-randomisation survival times to be jointly modelled
(Cowling et al. 2006). This method assumes that both these outcomes are
predicted by (unobserved) seizure rates, assuming that each patient has an un-
derlying constant seizure rate that we allow to vary depending on the following
baseline attributes: age at randomisation, sex and seizure type. Additionally
we suppose that the post-randomisation seizure rates will be reduced relative
to the baseline seizure rate. A greater reduction in the seizure rate results
in a longer time to seizure post-randomisation, indicating a better therapy.
We have modied this methodology however, to incorporate the inclusion of
possible cure rates.
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The data indicate that the risk of secondary generalised tonic-clonic seizures in
those patients that have presented with partial seizures only pre-randomisation
is low, regardless of EEG outcome. As would be expected, immediate treat-
ment with AEDs also had little benet in reducing the incidence of secondary
generalised tonic-clonic seizures post-randomisation. For this reason, the main
issue to be considered in this group of patients will be the eect of immediate
treatment on the frequency of their partial seizures. When this is examined,
treatment policy is not statistically signicant in reducing post-randomisation
seizure rates for those individuals presenting with partial seizures only. For
those groups of patients with tonic-clonic seizures pre-randomisation, immedi-
ate treatment is favoured. This observation is in keeping with the hypothesis
that partial seizures are generally more resistant to AEDs than tonic-clonic
seizures, be these generalised at onset or secondarily generalised. Indeed, it
could be argued that the main eects of currently available AEDs are to limit
the spread of seizure discharge within the brain, rather than to prevent the
initiation of seizures.
The ndings that we have observed may have some regulatory implications.
There has been some debate about the licensing of new AEDs. These are
brought to market through trials that compare add-on drugs with a placebo
in subjects with a history of pharmacologically resistant partial seizures. The
key outcomes will be the reduction in seizure frequency compared to placebo,
but the patients included are likely to have many more simple or complex par-
tial seizures than secondary generalised seizures. Thus it can be asked whether
such trials provide reasonable evidence of eectiveness against secondary gen-
eralised seizures.
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